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ABSTRACT
Targeting the Peripheral Immune System as a Source of
Precision Stroke Biomarkers: Implications for Clinical
Diagnostics and Immunotherapeutics
Grant C. O’Connell
Early and accurate diagnosis of stroke improves the probability of positive outcome,
however the tools available to clinicians for the identification of stroke are limited. It is well
established that the peripheral immune system responds robustly to ischemic brain injury, and
thus may be a viable source of stroke biomarkers. The objective of this work was to utilize high
throughput transcriptomics in combination with machine learning techniques to identify patterns
of gene expression in peripheral whole blood with the potential to diagnose ischemic stroke, and
to further determine the role of such gene expression patterns within the context of stroke
immunopathology. A discovery cohort was recruited comprised of 39 ischemic stroke patients and
24 controls, and peripheral blood was sampled at emergency department admission. Genomewide expression profiling was performed via microarray and a machine learning technique known
genetic algorithm k-nearest neighbors (GA/kNN) was then used to identify ten genes (ANTXR2,
STK3, PDK4, CD163, MAL, GRAP, ID3, CTSZ, KIF1B, and PLXDC2) whose coordinate pattern
of expression was able to discriminate between groups with 98.4% accuracy. The diagnostic
robustness of this pattern of expression was subsequently tested in an independent validation
cohort which included an additional 39 ischemic stroke patients and 50 controls, and was able to
discriminate between groups with 95.3% accuracy. Furthermore, leukocyte phenotyping of
validation cohort subjects suggested that this pattern of differential expression is a marker of
stroke-induced shifts in the cellular composition of the peripheral blood, as many of these ten
genes exhibited a strong pattern of lineage-specific expression on isolated leukocyte
subpopulations, and whole blood expression levels which were highly correlated with post-stroke
white blood cell differential. However, results of in-vitro experiments using primary human
leukocyte cultures suggested that one of these ten genes, CD163, which encodes a
lymphoinhibitory peptide known as soluble cluster of differentiation 163 (sCD163), may play a role
in modulation of stroke-induced peripheral immune phenotype, as monocyte-derived sCD163
present in the serum of ischemic stroke patients demonstrated an ability to inhibit the proliferation
of lymphocytes isolated from healthy donors. Due to the robust nature of these findings, the ten
transcriptional biomarkers identified by GA/kNN in our analysis warrant further evaluation to
determine their true diagnostic efficacy in the clinical setting. Furthermore, future exploration into
the role of sCD163 as a post-stroke immunomodulatory agent could provide novel insight
regarding the underlying mechanisms which drive stroke immunopathology.
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Chapter 1.

Introduction and specific aims:
There are currently 800,000 strokes reported annually in the United States, and stroke is responsible for
1 in every 19 mortalities.1 For those who survive, stroke constitutes a life altering event, with over 50% of patients
requiring significant impatient rehabilitation or skilled nursing assistance upon hospital discharge.1 It is well
established that early and accurate diagnosis improves acute ischemic stroke (AIS) outcome by increasing the
probability of successful intervention.2,3 Unfortunately, the current tools available to clinicians for diagnosis of
AIS are limited; diagnosis via assessment of overt patient symptoms lacks in accuracy,4 while diagnosis by
neuroradiological imaging is inaccessible early in the acute phase of care. As a result, there has been a recent
push for the identification of reliable peripheral blood stroke biomarkers which could be rapidly measured in
either the field or emergency department to expedite diagnosis and improve access to interventional treatment.5
The earliest stroke biomarker studies focused on the detection of brain-specific proteins which are
released into circulation as a result of brain damage. Unfortunately, a majority of biomarkers examined in these
studies failed to demonstrate clinically useful levels of sensitivity and specificity at early enough time points in
AIS progression to provide actionable diagnostic information.5–9 The reason this strategy may have failed to
identify biomarkers which are diagnostically robust with regards to acute triage may lie in that the presence of
brain-specific peptides in peripheral circulation following ischemic insult is likely largely dependent on apoptotic
and necrotic neuronal cell death, processes which do not fully progress until as late as 24 hours after symptom
onset.10,11 These early studies highlighted the necessity to target biological processes which show peripheral
evidence of stroke-induced alterations relatively early in AIS progression.
Stroke triggers an immediate systemic inflammatory response which results in a dramatic shift in the
phenotype of the peripheral immune system. The innate arm of the peripheral immune system undergoes rapid
expansion, as monocyte and neutrophil counts increase significantly in the hours following stroke onset. 12,13
Simultaneously, the adaptive arm of the immune system shifts into a state of suppression characterized by
lymphopenia and limited responsiveness.13–15 The relatively rapid nature of this response suggests that the
peripheral immune system may be an ideal source of biomarkers for early identification of AIS. Expectedly, proof
of concept genome-wide transcriptomic studies have demonstrated that gene expression in peripheral blood is
altered in the stroke pathology as a result of the peripheral immune response.16–19
However, these early stroke transcriptomics studies relied on methods commonly employed for basic
differential expression analysis which may not be well suited for biomarker selection; while candidate markers
identified in these studies showed promise, they failed to demonstrate levels of diagnostic robustness which
would suggest they could be clinically useful. The biomarker panels identified in these early studies were
comprised of candidate biomarkers discretely selected from genome-wide expression data based on arbitrary
fold change cut-offs and statistical significance in basic parametric testing; such strategies may be inadequate
for the identification of biomarkers, as such selection criteria do not directly infer discriminatory or prognostic
1

performance. Thus, strategies which select groups of candidate biomarkers based directly on discriminatory or
prognostic ability may prove more effective in identifying transcriptional biomarkers for the diagnosis of AIS.
Machine learning strategies may represent an optimal approach for biomarker identification based on such
selection criteria, as many foundational machine learning algorithms were developed for classification and
pattern recognition tasks.20
Analysis of high-dimensional gene expression data using a pattern recognition approach known as
genetic algorithm k-nearest neighbors (GA/kNN) has been successfully used in a small number of cancer studies
to identify diagnostically relevant biomarker panels with strong discriminatory ability.21–23 While this strategy has
proven robust in its applications in the field of cancer, it has yet to be utilized for biomarker discovery in the realm
of cardiovascular disease. We hypothesized that a similar approach combining high-throughput transcriptomic
profiling of the peripheral immune system with machine learning analysis would allow for the identification of
candidate AIS biomarkers with strong enough diagnostic performance to have potential for future clinical
implementation. Furthermore, we felt that exploration into the pathological role of candidate markers identified
with such an approach could not only increase their clinical utility, but also provide valuable insight into the
mechanisms which drive stroke immunopathology. Therefore, this work had two aims:
Aim 1: Use high-throughput transcriptomics in tandem with GA/kNN analysis to identify a pattern of

gene expression in peripheral blood capable of accurately detecting ischemic stroke during the acute
phase of care.
Aim 2: Evaluate the role of stroke-specific peripheral blood gene expression patterns within the context

of stroke immunopathology.
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Chapter 2.

Background and significance:
Stroke:
Stroke is the overarching classification for a cluster of cardiovascular pathologies in which cerebral blood
supply becomes disrupted; if this disruption in blood flow becomes prolonged, neural tissues experience oxygen
and glucose deprivation, which can ultimately result in neuronal cell death and permanent loss of function. About
10% of stroke cases are hemorrhagic in nature, in which blood flow disruption is a result of a ruptured
intracerebral blood vessel and subsequent intracerebral bleeding. The remaining number of stroke cases are
ischemic in nature, in which blood flow is disrupted as a result of a thrombotic or embolic cerebrovascular
occlusion. Collectively, stroke is the fifth leading cause of death in the United States, and the leading cause of
disability. Currently, the direct health care costs associated with stroke are approaching 80 billion dollars
annually, a large proportion of which are expenditures associated with post-hospital rehabilitation.1
A need for stroke biomarkers:
It is well established that the primary mechanism by which ischemic stroke outcome can be improved is
through timely diagnosis and reperfusion of ischemic tissue via interventional therapies. Currently, there are
only two FDA approved interventional strategies for AIS which have shown significant patient benefit:
thrombolysis via intravenous administration of recombinant tissue plasminogen activator (rtPA), and physical
recannulation via endovascular mechanical thrombectamy.24 Despite the fact that these interventions are known
to limit primary tissue damage and reduce rates of morbidity and mortality, less than five percent of AIS patients
receive treatment.25 One of the most promising avenues by which treatment rates could be increased is through
improvements in the diagnostic process.
Due to the risk of life threatening adverse events, a definitive diagnosis of ischemic stroke is required
prior to either thrombolytic or endovascular intervention.26 Currently, the only way to obtain a definitive diagnosis
is through neuroradiological imaging via computerized tomography (CT) or magnetic resonance imaging (MRI).
Unfortunately, these imaging techniques are inaccessible in the field, and often not immediately available in
hospitals without dedicated stroke centers, such as smaller facilities and those which serve rural areas.27 This is
problematic in that the benefits of interventional therapies are time limited, and they are only accessible at a
select number of hospitals. Because the efficacy of rtPA decreases and the risk of adverse events increases as
ischemic stroke pathology progresses, it is currently recommended that rtPA be administered within three and a
half hours of symptom onset.28 While the therapeutic time window is not as limited for endovascular intervention
is for thrombolytic therapy, endovascular thrombectamy still must be performed within seven hours of symptom
onset to show significant benefit.29 Furthermore, because both thrombolytic and endovascular interventions
require specialized personal, they are only performed at a limited number of hospitals which carry primary and
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comprehensive stroke center designations.24 Thus, for patients to receive access to treatment, they must arrive
at a stroke-ready hospital and receive a definitive diagnosis within a relatively short period of time.
In the prehospital, setting this can be facilitated through quick and confident recognition of stroke by first
responders and emergency medical technicians, allowing for patients to be transported directly to hospital
facilities which are designated for stroke care, increasing the chances of appropriate treatment and improved
outcome.30 With regards to self-admitted patients and patients who are already in hospital care, the ability of
hospital clinicians to confidently recognize stroke allows for immediate referral to a stroke team in the case of
hospitals which have stroke center designations, or transfer to such a facility in the case of hospitals which are
not equipped to deal with stroke. Unfortunately, inaccessibility to neuroradiological imaging means that these
triage decisions are based on the assessment of overt patient symptoms using stroke recognition and severity
scales such as the Cincinnati prehospital stroke scale (CPSS) and National Institutes of Health stroke scale
(NIHSS).26 In the hospital setting, the ability to identify stroke with such assessments is highly inconsistent, with
an estimated sensitivity ranging from 44-85%, and specificity ranging between 64-98%, depending on the scale
used and experience of the clinician.4 The sensitivity and specificity of these assessments is even lower in the
pre-hospital setting, where in some scenarios the ability to recognize stroke has been shown to be only
marginally better than random.31
The development of an accurate imaging-independent tool for diagnosis of AIS would allow clinicians to
make more informed pre-hospital and in-hospital triage decisions, ultimately improving patient outcomes by
expediting access to interventional treatment. One potential way such a tool could be the developed is through
the discovery of stroke-specific peripheral blood biomarkers which could be incorporated into rapid point of care
tests. For this reason, there has been a substantial push for the identification of peripheral blood biomarkers with
the potential for stroke diagnosis.
Early stroke biomarker studies:
Initial stroke biomarker studies focused largely on plasma detection of brain-specific proteins which are
released into circulation as a result of brain damage, along with protein markers of thrombosis. Some of the most
widely characterized of these candidate biomarkers include calcium-binding protein B (S100B), a glial-specific
calcium binding protein, glial fibrillary acidic protein (GFAP), a filamentous protein produced predominantly by
astrocytes, Von-Willebrand factor (vWF), a circulating glycoprotein involved in coagulation, and Fibrin D-dimer,
a fibrin degradation product associated with thrombosis. Unfortunately, these and similar markers have failed to
demonstrate clinically useful levels diagnostic accuracy at early enough time points in AIS progression to provide
actionable diagnostic information, with even the most promising panels failing to achieve sensitivities and
specificities approaching 90% when tested in a clinically relevant manner.5–9
The reason this strategy may have been unsuccessful in identifying biomarkers which are diagnostically
robust with regards to acute triage likely lies in that the presence of brain-specific peptides in peripheral
4

circulation following ischemic insult is likely largely dependent on apoptotic and necrotic neuronal cell death,
processes which do not fully progress until as late as 24 hours after symptom onset.10,11 Thus, these early studies
highlighted the necessity to target biological processes which show peripheral evidence of stroke-induced
alterations relatively early in AIS progression.
The peripheral immune response as a source of stroke biomarkers:
It is becoming increasingly evident that ischemic stroke produces a robust systemic inflammatory
response which results in a dramatic shift in the complexion of the peripheral immune system. Upon the onset
of ischemia, signals initiated within the ischemic brain region result in near-immediate activation of innate
peripheral immune system and simultaneous suppression of the adaptive peripheral immune system. Due to the
rapid nature of this response, and the fact that it has a peripheral component, make it an appealing biological
process to target in terms a potential source of stroke biomarkers.
At the onset of AIS, the local inflammatory cascade is initiated within the occluded cerebrovasculature.
Vascular occlusion immediately results in intravascular ischemia, alterations in shear stress, and production of
reactive oxygen species. Collectively, these physical and molecular changes trigger platelet activation,
upregulation of adhesion molecules on endothelial cells, and the rapid release of proinflammatory cytokines by
the cells of the neurovascular unit.32 Innate peripheral leukocyte populations in the immediate area of the insult
respond to these collective stimuli with the release of matrix metalloproteinases (MMPs), while endothelial cells
coordinately downregulate the expression of junctional proteins, ultimately resulting in increases in pericellular
permeability of the endothelium.33 This increase in pericellular permeability allows for the extravasation of
peripheral immune cells and peripheral proteins into the perivascular space. Within the perivascular space,
hypoxia and increased accumulation of proinflammatory cytokines trigger the activation of local macrophages
and mast cells, which then perpetuate the inflammatory cascade, promoting further infiltration of peripheral
immune populations.34 While the immune response observed within the cerebrovasculature and perivascular
space occurs almost immediately upon blood flow disruption, the immune response which occurs within the
affected parenchymal brain tissue is slightly delayed, as it is highly dependent on the progression of ischemiainduced cell damage and activation of local microglial populations.
As ischemia initially spreads within the parenchyma, nucleotides such as adenosine triphosphate (ATP),
as well as neurotransmitters, are released from neurons due to stress-induced depolarization. As a result,
extracellular ATP and neurotransmitter levels rise dramatically within minutes of ischemic onset, priming local
microglial populations.35 As ischemia continues to progress, prolonged glucose and oxygen deprivation trigger
the onset of neuronal cell death, during which the structural integrity of the plasma membrane is compromised,
and intracellular molecules which are associated with cellular damage are released into the extracellular space.36
These damage-associated molecules provide activating signals to microglia via various pattern recognition and
scavenger receptors; in addition to ATP, other intracellular molecules containing purines such as uracil triphosphate (UTP) bind and activate purinoreceptors.35 Furthermore, intracellular proteins such as high mobility
5

group box 1 (HMGB1), amyloid beta (Aβ), and heat shock proteins (HSPs) bind and activate toll-like receptors
(TLRs).37 The cumulative effect of these activating signals is increased activity of pro-inflammatory intracellular
signaling pathways such as the nuclear factor kappa-B (NF-kB) pathway, which drive M1 microglial polarization
and production of proinflammatory cytokines and chemokines. Pro-inflammatory cytokines and chemokines
released by microglia activate local astrocytes and promote the migration of peripheral immune cells from the
perivascular space into the damaged parenchyma.38
Infiltrating innate immune cells, including neutrophils and monocyte-derived M1 activated macrophages,
provide a population of phagocytes which will ultimately play a role in the clearance of apoptotic and necrotic
debris, which is necessary for later repair and remodeling of the lesion.38 The inflammatory milieu within and
around the damaged brain tissue initiates sympathetic nervous system signaling to peripheral immune organs,
allowing for a coordinated peripheral response which can further support the innate immune activities occurring
within the ischemic region.39 Sympathetic innervation of bone marrow triggers the release of newly-formed
myeloid immune cells into peripheral circulation40 while sympathetic signaling to the spleen promote the release
of sequestered neutrophils and monocytes.41 These newly-circulating innate immune cells are then free migrate
to the ischemic region and contribute to the population of infiltrating peripheral innate immune cells, driven by
chemotactic gradients originating from the ischemic tissue.38
While infiltrating innate peripheral immune populations play a necessary role in the acute response to
injury, excessive infiltration of peripheral adaptive immune populations can be pose a threat which has the
potential to dramatically exacerbate the injury. In the absence of neurodegenerative disease or neural trauma,
the peripheral adaptive immune system does not come in contact with central nervious system (CNS) antigens.42
Disruption of the blood brain barrier and the glia limitans during the acute inflammatory phase of stroke, as well
as chemotactic gradients generated via the local immune response, not only allow for the recruitment of
peripheral innate immune populations into the infarct region, but also allow for the infiltration of peripheral
lymphocytes.38 Major histocompatibility (MHC) molecules and costimulatory proteins required for antigen
presentation are upregulated on activated macrophages and microglia within the damaged tissue43,44;
phagocytosis of neuronal debris and subsequent presentation of neuronal antigens by these innate immune
populations has the potential to activate infiltrating peripheral lymphocytes and trigger an adaptive autoimmune
response.45 The presence of lymphocyte infiltrates in the brain and elevated titers of antibodies against brainspecific antigens have been observed months after injury in some cases.46 In these scenarios, this long-term
adaptive response helps maintain an inflammatory environment at the site of injury, which promotes secondary
tissue damage via prolonged innate immune system activity.47
As a neuroprotective mechanism to limit such an adaptive immune response, the peripheral immune
system shifts into a state of suppression.48 Sympathetic signaling initiated in the ischemic brain to peripheral
lymphoid organs promotes the sequestration of adaptive immune populations,39 and circulating lymphocyte
counts drop in the hours following ischemic onset.13,14 In addition to sequestration, peripheral lymphocytes
6

undergo functional changes as a result of ischemic insult which make them resistant to antigen-stimulated
activation; lymphocytes obtained from stroke patients have been shown to exhibit impaired proliferation and
altered cytokine production when stimulated with common pathogen-derived antigens.14,49–51 While the exact
molecular mechanisms which drive these functional changes remain unclear, they are believed to be at least in
part driven by stroke-induced alterations in circulating factors, as serum from stroke patients has been shown to
inhibit the proliferation of lymphocytes derived from heathy donors.52
This stroke induced-shift in the state of the peripheral immune system towards an innate-activated,
adaptive-suppressed phenotype occurs relatively quickly following ischemic onset, as alterations in peripheral
white blood cell differential are often already observable at emergency department admission.12–14 The rapidness
of this response, in combination with the fact that peripheral immune cells are readily assessable via liquid
biopsy, makes the peripheral immune system a potential source of robust ischemic stroke biomarkers.
Preliminary stroke biomarker studies targeting the peripheral blood transcriptome:
Initial studies investigating the peripheral immune response to stroke as a potential source of biomarkers
chose to do so via microarray-based genome-wide expression profiling. This represents strong strategy, in that
it allows for the parallel analysis of thousands of potential RNA biomarkers, increasing the likelihood of identifying
transcripts with strong diagnostic potential.
In the first of these studies, Moore et al.17 identified hundreds of transcripts which were differentially
regulated in isolated peripheral blood mononuclear cells (PBMCs) obtained from a small cohort of AIS patients
relative to those obtained from neurologically asymptomatic healthy control subjects. Furthermore, they were
able to demonstrate that the coordinate expression levels of 22 of these differentially regulated genes could
discriminate between AIS patients and control subjects with 78% sensitivity and 80% specificity. While the results
of this study demonstrated strong proof of principle, the fact that gene expression profiling was performed in
PBMCs limited potential translation of the identified panel for diagnostic use in the acute care setting, as the
preparation of PBMCs is time consuming and requires laboratory equipment.
A pilot study performed by Tang et al.18 and a subsequent validation study performed by Stamnova et
al.19 addressed this limitation by performing gene expression profiling in whole blood samples obtained from AIS
patients and neurologically asymptomatic healthy control subjects at 3, 5, and 24 hours post symptom onset.
Unfortunately, gene expression data from a single time point was not adequate to differentiate between AIS
patients and control subjects with noteworthy levels of accuracy, however, a panel of 18 candidate genes was
described which demonstrated the ability to discriminate between groups with 93.5% sensitivity and 89.5%
specificity using combined expression data generated from all three blood draws. Several of these 18 genes
were further confirmed as being differentially regulated in AIS in an independent investigation by Barr et al.,16
however their diagnostic utility was not assessed. While these studies once again provided promising proof of
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principle, the necessity to obtain multiple blood samples to achieve high levels of sensitivity and specificity limited
this candidate biomarker panel with regards to implementation for acute stroke triage.
Collectively, these preliminary studies demonstrated that the transcriptome of the peripheral immune
system is responsive to stroke, and that stroke-induced changes in peripheral blood gene expression can be
implemented for diagnostic purposes. Technical limitations aside, in terms of diagnostic accuracy, the candidate
biomarker panels identified these early transcriptomic studies dramatically outperformed a wide majority of the
candidate protein biomarkers which had been investigated previously. However, these panels were still far from
being diagnostically perfect, despite only being tested against healthy control subjects absent of cardiovascular
disease (CVD) risk factors.
Machine learning for biomarker discovery:
One major reason these early panels of transcriptional biomarkers may have failed to demonstrate robust
diagnostic ability may lie in how they were selected. The panels identified in these initial stroke transcriptomics
studies were comprised of candidate biomarkers discretely selected from genome-wide expression data based
on arbitrary fold change cut-offs and statistical significance in parametric testing. Such strategies are commonly
employed in differential expression studies, however may be inadequate for the identification of biomarkers, as
such selection criteria do not directly infer discriminatory or prognostic performance. Furthermore, such selection
techniques do little to inform about the collective diagnostic potential the candidate markers, as each candidate
marker of the resultant panel is being selected as part of a discrete evaluation. Thus, strategies which select
groups of candidate biomarkers based directly on collective discriminatory or prognostic ability may prove more
effective in identifying transcriptional biomarkers for the diagnosis of AIS. Machine learning strategies may
represent an optimal approach for biomarker identification based on such selection criteria, as many foundational
machine learning algorithms were developed for classification and pattern recognition tasks.20
Analysis of high-dimensional gene expression data using a pattern recognition approach known as
genetic algorithm k-nearest neighbors (GA/kNN) has been successfully used in a small number of cancer studies
to identify diagnostically relevant biomarker panels with strong discriminatory ability.21–23 The GA/kNN approach
combines a powerful search heuristic, GA, with a non-parametric classification method, kNN. In GA/kNN
analysis, a small combination of genes (referred to as a chromosome) is generated by random selection from
the total pool of gene expression data (Figure 1A). The ability of this randomly generated chromosome to
discriminate between sample classes is then evaluated using kNN. In this evaluation, each sample is plotted as
a vector in a multi-dimensional feature space where the coordinates of the vector are comprised of the expression
levels of the genes of the chromosome. The class of each sample is then predicted based on the majority class
of the nearest neighbors, or other samples which lie closest in Euclidian distance within the feature space (Figure
1B). The ability of the chromosome to discriminate between classes is quantified as a fitness score, or the
proportion of samples which the chromosome is correctly able to classify. A termination cutoff (minimum
proportion of correct classifications) determines the level of fitness required to pass evaluation. A chromosome
8

Figure 1. GA/kNN paradigm used for the selection of transcriptional biomarkers from high-dimensional
expression data. (A) A first generation chromosome is generated via random selection from the total pool of gene
expression data. (B) The ability of the first generation chromosome to discriminate between groups is evaluated using
kNN. (A) If the chromosome passes evaluation, it is added to the pool of near-optimal solutions. If the chromosome
fails evaluation, it undergoes mutation and re-evaluation until a near-optimal solution is found. (C) This search is
repeated to generate a pool containing hundreds of thousands of near-optimal solutions. (D) Genes are then ranked
based on the number of times they appear in the near-optimal solution pool. (E) The combined discriminatory ability
of the top ranked genes is then tested in leave one out cross validation via kNN.

which passes kNN evaluation is labeled as a near-optimal solution and recorded, while a chromosome which
fails undergoes repeated cycles of mutation and re-evaluation until a near optimal solution is reached (Figure
1A). This entire search paradigm is performed multiple times (typically hundreds of thousands) to generate a
heterogeneous pool of near-optimal solutions (Figure 1C). The discriminatory ability of each gene is then ranked
according to the number of times it appears in the near-optimal solution pool (Figure 1D), and the collective
discriminatory ability of the top ranked genes can then be tested via kNN in a leave one out cross validation
(Figure 1E). This approach has been utilized to generate biomarker panels capable of optimally discriminating
9

between cancerous and non-cancerous colon biopsies,23 primary and metastatic melanoma tumors,21 as well as
between B-cell lymphoma sub-types,22 all with accuracies ranging between 95 and 100%.
While this approach combining high-throughput transcriptomics with GA/kNN analysis has proven robust
in several applications in the field of cancer, it has yet to be utilized for biomarker discovery in the realm of
cardiovascular disease (CVD). We hypothesized that a similar approach combining high-throughput
transcriptomic profiling of the peripheral immune system with machine learning analysis would allow for the
identification of candidate AIS biomarkers with strong enough diagnostic performance to have potential for future
clinical implementation. Furthermore, we felt that exploration into the pathological role of candidate markers
identified with such an approach would not only increase their clinical utility, but also provide valuable insight
into the mechanisms which drive stroke immunopathology.

10

Chapter 3.

Results:

Machine learning for identification of candidate ischemic stroke biomarkers:
In order to identify transcriptional signatures within the peripheral immune system with the potential for
identification of AIS, we first recruited a modestly-sized discovery cohort comprised of 39 imaging-confirmed AIS
patients and 24 neurologically asymptomatic control subjects (Table 1). Peripheral whole blood was sampled
from patients at emergency department admission, and genome-wide expression profiling was performed via
microarray. Gene expression data were subjected to GA/kNN analysis, and genes were ranked based on the
ability of their expression levels to discriminate between AIS patients and controls, according to the number of
times they were selected as part of a near-optimal solution (Figure 2A). The expression levels of top 50 genes
identified by GA/kNN displayed a strong ability to discriminate between groups using kNN in leave one out cross
validation; the combined expression levels of as few as four of the top 50 ranked genes were able to identify
subjects in the discovery cohort the with levels of accuracy in excess of 98% (Figure 2B).
We then wanted to confirm that the top genes identified in our GA/kNN analysis that were truly optimal
in terms of discriminatory ability. To do this, we compared the ability of the expression levels of top 50 genes
selected by GA/kNN to differentiate between stroke patients and controls to that of genes selected at random.
Specifically, we compared the accuracy of GA/kNN-selected genes to the accuracy of 50 sets of 50 genes
randomly generated from the total pool of gene expression data, as well to the accuracy of 50 sets of 50 genes
randomly selected from a sub-pool of genes which displayed greater than 1.7 fold differential regulation between
groups. The top genes selected by GA/kNN performed significantly better than genes selected at random
genome-wide, as well as significantly better than genes selected at random from those which were differentially
regulated greater than 1.7 fold (Figure 2C). Collectively, the results of this analysis, in combination with the levels
Table 1. Discovery cohort clinical and demographic characteristics.

Continuous variables compared with student’s t-test (t), categorical variables compared with chi-squared test (χ2)
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Figure 2. Top 50 genes selected by GA/kNN for identification of AIS. (A) The top 50 peripheral blood transcripts
ranked by GA/kNN based on their ability to discriminate between AIS patients and neurologically asymptomatic
controls in the discovery cohort. (B) Combined ability of the expression levels of top 50 genes selected by GA/kNN to
discriminate between AIS patients and neurologically asymptomatic controls in the discovery cohort using kNN. (C)
Ability of the expression levels of the top 50 genes selected by GA/kNN to discriminate between neurologically
asymptomatic controls and AIS patients via kNN compared to the expression levels of genes selected at random. The
accuracy of the top 10 genes selected by GA/kNN was specifically tested against the accuracy of randomly selected
genes using single sample two-way t-test.

of accuracy observed, suggest that our biomarker discovery strategy was effective at selecting genes with
optimal diagnostic potential in terms of the subjects of the discovery cohort. Because the use of genes beyond
the top ten did not appear to improve overall accuracy (Figure 2B), and displayed diminishing diagnostic
robustness relative to genes selected at random (Figure 2C), we chose to focus on only the top ten genes
(ANTXR2, STK3, PDK4, CD163, MAL, GRAP, ID3, CTSZ, KIF1B, and PLXDC2) for the remainder of our
analysis.
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Figure 3. Differential expression of top ranked genes within the discovery cohort. (A) Peripheral blood
differential expression of the top ten genes selected by GA/kNN in discovery cohort neurologically asymptomatic
controls and AIS patients, with fold changes reported relative to control. Statistical significance of intergroup
differences in gene expression was determined via two-sample two-way t-test, and p-values were corrected to account
for multiple comparisons via Holm’s Bonferroni method. (B) Coordinate pattern of peripheral blood expression across
the top ten genes plotted for individual subjects in both experimental groups. (C) Composite RNA expression levels
of the top ten genes generated via principal components analysis.

When comparing the peripheral blood expression levels of the top ten genes between AIS patients and
controls, the magnitude of differential expression was modest in terms of fold change in the case of most genes,
however differences in expression levels between groups were highly consistent across all subjects, which was
reflected by high levels of statistical significance in parametric statistical testing (Figure 3A). The combined
discriminatory power of the top ten genes was evident when their coordinate expression levels were plotted on
a continuum for each individual subject; the overall pattern of expression was strikingly different between AIS
patients and controls, and it was clear that the overall pattern of expression was more diagnostically powerful
than the expression levels of any given gene on its own (Figure 3B).
Next, we wanted to determine whether potentially confounding intergroup differences in clinical and
demographic characteristics (Table 1) influenced the expression levels of the top ten genes. In order to more
intuitively explore the relationship between the pattern of gene expression observed across the top ten genes
and these potentially confounding factors, we first used principal components analysis to describe the expression
levels of the top ten genes as single composite RNA expression variable. The expression levels of the top ten
genes were highly correlated, and a single principal component was able to capture 70% of the collective
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Figure 4. Use of principal components analysis for generation of a composite RNA expression variable
summarizing the coordinate expression levels of the top ten genes. (A) Correlation matrix depicting the
correlations between the expression levels of the top ten genes identified by GA/kNN in the discovery cohort. Strength
of correlations were tested via Spearman’s rho. (B) Principal component loadings and coefficients used for generation
of the composite RNA expression variable.

Figure 5. Influence of potentially confounding clinical and demographic characteristics on the expression
levels of the top ten genes. (A) Multiple regression model generated by regressing potentially confounding clinical
and demographic characteristics against the composite RNA expression levels of the top ten genes selected by
GA/kNN in the discovery cohort. (B) Graphical representation of the relative contribution of each regressor towards
the total variance in composite RNA expression explained by the model.

variance in expression (Figure 4A). The result component scores (composite RNA expression) were strongly
correlated with the expression levels of each of the individual candidate genes (Figure 4B), and visually appeared
to summarize the gene expression pattern well (Figure 3C). Stroke, age, anticoagulant status, hypertension,
antihypertensive status, dyslipidemia, history of myocardial infarction, and history of atrial fibrillation were then
regressed against the composite RNA expression levels of the top ten genes using multiple regression. We
subsequently performed variance decomposition via the Lindeman-Merenda-Gold (LMG) method to estimate
the relative contributions of each regressor to the total variance in composite RNA expression explained by the
resultant regression model.53
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Figure 6. Influence of stroke severity and time to blood draw on the coordinate expression levels of the top
ranked genes in discovery cohort AIS patients. (A) Relationship between stroke severity, as assessed by NIHSS,
and composite RNA expression levels of the top ten genes in discovery cohort AIS patients. (B) Relationship between
time from symptom onset to blood draw and composite RNA expression levels of the top 10 genes in discovery cohort
AIS patients, with indication of stroke severity. Strength of correlations were tested via Spearman’s rho.

Stroke remained significantly associated with the composite RNA expression levels of the top ten genes
after accounting for all potentially confounding factors included in the model (Figure 5A), and was responsible
for a majority of the explained variance (77.9%, Figure 5B). In terms of potentially confounding factors, both antihypertensive status and anticoagulant status were significantly associated with the composite RNA expression
levels of the top ten genes after accounting for all other regressors (Figure 5A), however these associations only
accounted for a small amount of the variance in composite RNA expression explained by the model (6.5% and
4.5% respectively, Figure 5B). Results of this multiple regression analysis were supported by the results of a
more traditional logistic regression analysis in which the composite RNA expression levels of the top ten genes
were identified as the only significant predictor of stroke when considering the same potentially confounding
covariates (Supplemental Table 1). Taken as a whole, these findings suggest that the pattern of differential
expression observed across the top ten genes between groups is highly associated with stroke independently of
the assessed potential confounding factors. While these findings do suggest that antihypertensive status and
anticoagulant status may influence the expression levels of the top ten genes, the effect of this influence on
expression levels are likely minimal relative to the effect of stroke, and intergroup differences in these factors
were likely not significant drivers of the selection of these genes by GA/kNN.
We additionally used this composite RNA expression variable to examine the potential influence of stroke
severity and time to blood draw on the pattern of gene expression observed across the top ten genes in the
discovery cohort. The composite RNA expression levels of the top ten genes displayed a significant positive
association with stroke severity as assessed by the NIHSS (Figure 6A), suggesting that the expression levels of
the top ten genes are likely directly responsive to stroke pathology. We observed a weak nonsignificant negative
relationship between the composite RNA expression levels of the top ten genes and the time from symptom
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Table 2. Validation cohort clinical and demographic characteristics.

Continuous variables compared with student’s t-test (t), categorical variables compared with chi-squared test (χ2)

onset to blood draw (Figure 6B). However, this negative relationship was likely driven by the influence of stroke
severity, given that the composite expression levels of these genes were positively associated with stroke
severity, and patients undergoing more severe strokes generally presented to the emergency department earlier
than patients undergoing less severe strokes (Figure 6B). Collectively, these observations suggest that the
stroke-induced differential expression of the top ten genes may have additional utility for the stratification of
stroke severity, and is relatively temporally stable during the acute phase of care.
In order to evaluate the generalizability of the pattern of differential expression identified by GA/kNN in
the discovery cohort, we next tested the diagnostic ability of the top ten ranked genes in an independent
validation cohort enrolled via a second geographically and socioeconomically distinct clinical site (see
experimental procedures section). This validation cohort was comprised of an additional 39 AIS patients along
with two different control groups, one consisting of 30 neurologically asymptomatic controls, and the other
consisting of 20 acute stroke mimics (Table 2). Peripheral blood samples were once again obtained from patients
at emergency department admission, and the expression levels of the top ten genes identified by GA/KNN in the
discovery cohort were measured via qRT-PCR.
The overall pattern of differential expression between AIS patients and asymptomatic controls observed
across the top 10 genes in the discovery cohort was also seen when comparing AIS patients and asymptomatic
controls in the validation cohort (Figure 7A). The strong ability of the top ten genes to differentiate between stroke
patients and asymptomatic controls in the discovery cohort using kNN was also recapitulated in the validation
cohort; the expression levels of the top ten genes used in combination were able to classify 95.6% of subjects
correctly with a sensitivity of 92.3% and a specificity of 100% (Figure 7B).
When comparing AIS patients to stroke mimics, the overall pattern of differential expression observed
across the top ten genes was identical to that observed when comparing AIS patients to asymptomatic controls,
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Figure 7. Differential expression and discriminatory ability of top ranked genes within the validation cohort.
(A) Peripheral blood differential expression of the top ten genes between validation cohort neurologically
asymptomatic controls and AIS patients. (B) Combined ability of the expression levels of the top ten genes to
discriminate between neurologically asymptomatic controls and AIS patients. (C) Peripheral blood differential
expression of the top ten genes between acute stroke mimics and AIS patients. (D) Combined ability of the expression
levels of the top ten genes to discriminate between acute stroke mimics and AIS patients. All gene expression values
are reported as fold change relative to control. Statistical significance of intergroup differences in gene expression
was determined via two-sample two-way t-test, and p-values were corrected to account for multiple comparisons via
Holm’s Bonferroni method.

however the magnitude of these expression differences was smaller in the case of several genes (Figure 7C).
Despite this reduction in the magnitude of differential expression, the expression levels of the top ten genes used
in combination were still able to accurately discriminate between AIS patients and stroke mimics, classifying
94.9% of subjects correctly with a sensitivity of 97.4% and a specificity of 90.0% (Figure 7D). However, it is
important to note that it was evident that all ten genes were required to achieve high levels of diagnostic accuracy
when comparing AIS patients to stroke mimics (Figure 7D), whereas similar levels of accuracy could be achieved
with as few as the top four markers when comparing AIS patients to neurologically asymptomatic controls in both
the discovery cohort (Figure 2B) and the validation cohort (Figure 7B). Despite this, the collective validation
cohort results supported those of the discovery cohort, and provide further evidence that the top ten markers
selected by GA/kNN in our analysis have high potential performance for identification of AIS.
Note: Full manuscript associated with these results can be found in Appendix, Manuscript 1.

Role of stroke-identifying biomarkers in immunopathology:
In order to gain a better understanding regarding the potential role of the top ten genes in the strokeinduced peripheral immune response, we next explored the relationship between their peripheral blood
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Figure 8. Relationships between whole blood expression levels of transcriptional stroke biomarkers and
peripheral immune status in AIS patients. Relationship between peripheral whole blood expression levels of (A)
ANTXR2, (B) STK3, (C) PDK4, (D) CD163, (E) MAL, (F) GRAP, (G) ID3, (H) CTSZ, (I) KIF1B, and (J) PLXDC2 and
NMLR in validation cohort AIS patients at emergency department admission. Strength of correlations were tested via
Spearman’s rho.

expression levels and white blood cell differential within the validation cohort AIS group. For this analysis, we
choose to summarize white blood cell differential in terms of the neutrophil-monocyte to lymphocyte ratio
(NMLR), as it provides a single variable which can intuitively be used to infer peripheral immune status within
the context of the known stroke-induced shift towards innate immune activation and adaptive immune
suppression.
The whole blood expression levels of each of the seven genes which we observed as up-regulated in
AIS were to some degree positively associated with NMLR (Figure 8A, 8B, 8C, 8D, 8H, 8I, 8J). Conversely, the
whole blood expression levels of all three genes which we observed as being down-regulated in AIS were
negatively associated with NMLR (Figure 8E, 8F, 8G). We hypothesized that this phenomenon was a result of
two not-necessarily distinct possibilities: that changes in the expression of these genes observed with AIS at the
whole blood level are simply a marker of stroke-induced shifts in white blood cell differential, or that changes in
the transcription of these genes at the level of individual cells help drive the stroke-induced alterations in the
phenotype of the peripheral immune system.
To begin to understand which of these of possibilities underlie the relationship between the expression
levels of the top ten genes and white blood cell differential following AIS onset, we looked to identify where these
genes are expressed in the peripheral immune system. To do this, we measured the basal expression levels of
the ten candidate genes on six subpopulations of immune cells isolated from the peripheral blood of three healthy
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Figure 9. Expression levels of the ten candidate transcriptional biomarkers on isolated leukocyte subpopulations. Expression levels of (A) ANTXR2, (B) STK3, (C) PDK4, (D) CD163, (E) MAL, (F) GRAP, (G) ID3, (H)
CTSZ, (I) KIF1B, and (J) PLXDC2 in peripheral whole blood and isolated leukocyte populations obtained from one
male and two female healthy donors. Expression levels are presented as fold change relative to the population of
lowest expression, and were statistically compared via one-way ANOVA.

donors. Interestingly, almost every gene exhibited some degree of lineage-specific expression. Each of the
seven genes which we observed as being up-regulated in the peripheral blood in response to stroke were all
predominantly expressed in cell populations of myeloid origin (Figure 9A, 9B, 9C, 9D, 9H, 9I, 9J). Conversely,
all of genes which we observed as being downregulated were predominantly expressed in cells of lymphoid
origin (Figure 9E, 9F, 9G). In several cases, the difference in expression between myeloid and lymphoid
populations was quite substantial, in excess of hundred-fold.
Taken as a whole, the relationships we observed with NMLR, along with the strong pattern of lineagespecific expression, suggest that the expression levels of these genes in whole blood likely serve as markers of
the collective cellularity of the peripheral immune system. This insinuates that the changes in the expression of
these genes which we observed in AIS in whole blood are reflective of stoke-induced shifts in white blood cell
count, and likely not a result of alterations in transcription at the level of individual cells. This ultimately suggests
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Table 3. Protein products associated with the top ten genes selected by GA/kNN.

that many of these genes may not play a substantial mechanistic role as drivers of stroke immunopathology, as
genes which mechanistically drive the changes observed in the peripheral immune system following stroke are
likely ones which undergo true stroke-induced differential transcription. A scenario in which this may not hold
true however, is in the case of genes which encode for secreted proteins; circulating concentrations of secreted
lineage-specific proteins may become altered by virtue of changes in cell count alone, independently of any
change in transcription or translation at the level of individual cells.
Note: Full manuscript associated with these results can be found in Appendix, Manuscript 2.

CD163 as a potential modulator of the stroke-induced peripheral immune response:
While a majority of the top ten genes identified in our analysis encode for intracellular proteins
(Summarized in Table 3), one gene in particular, CD163, encodes for a protein known as cluster of differentiation
163 (CD163) which has the potential for secretion.54 CD163 is a membrane-bound scavenger receptor for
extracellular hemoglobin which is believed to be expressed exclusively within the innate immune system,55 where
it is predominantly found on monocytes and macrophages,56 and to a lesser extent on neutrophils.57 Various
stimuli can trigger CD163 ectodomain shedding via cleavage by the metalloprotease ADAM metallopeptidase
domain 17 (ADAM17),58,59 resulting in generation of a soluble truncated peptide (sCD163) which has been shown
in multiple studies to directly interact with lymphocytes and inhibit antigen-induced proliferation.60–62 Interestingly,
other groups have reported elevations in ADAM17 activity in animal models of ischemic brain injury,63–65 as well
as stroke-induced increases in peripherally circulating levels of various ADAM17 substrates such as tumor
necrosis factor alpha (TNFα) in human subjects.66,67 Therefore, it is possible that stroke induces a rise in
peripherally circulating levels of sCD163 via coordinate increases in the number of CD163 expressing innate
immune cells and elevations in ADAM17 activity; such a rise in sCD163 levels could subsequently contribute to
suppression of the adaptive immune system via the inhibitory effects of sCD163 on lymphocyte activity.
In order to address this hypothesis, we first assessed peripheral blood ADAM17 activity and circulating
sCD163 levels in the peripheral blood of validation cohort subjects via enzyme activity assay and ELISA,
respectively. ADAM17 activity was significantly elevated in the peripheral whole blood of AIS patients relative to
that of both neurologically asymptomatic controls and acute stroke mimics (Figure 10C). Likewise, plasma levels
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Figure 10. ADAM17 and CD163 expression in the peripheral blood of validation cohort subjects. mRNA
expression of (A) ADAM17 and (B) CD163 in peripheral whole blood obtained from AIS patients and controls, with
expression levels presented as fold difference relative to asymptomatic control group. (C) Cellular ADAM17 activity
in the peripheral whole blood of AIS patients and controls. (D) Plasma concentrations of sCD163 in AIS patients and
controls. (E) Relationship between peripheral blood cellular ADAM17 activity and NIHSS within the AIS group. (F)
Relationship between plasma sCD163 levels and NIHSS within the AIS group. Intergroup comparisons were made
via one-way ANOVA with subsequent Bonferonni post-hoc, while strength of correlational relationships were tested
via Spearman’s rho.

Figure 11. Relationship between plasma sCD163 levels and post-stroke peripheral immune status.
Relationships between plasma sCD163 levels and (A) absolute lymphocyte counts, (B) absolute monocyte counts,
and (C) absolute neutrophil counts in the peripheral blood of validation cohort AIS patients. strength of correlational
relationships were tested via Spearman’s rho.

of sCD163 were significantly higher in AIS patients relative to both control groups (Figure 10D). Furthermore,
both ADAM17 activity and plasma sCD163 levels displayed positive associations with stroke severity in terms of
NIHSS (Figure 10E, 10F) and infarct volume (Supplemental Figure 1A, 1B); while our relatively small sample
size and the variability inherent to such measures of injury status kept these associations from reaching statistical
significance, the relationships observed provide tentative evidence that both factors are potentially directly
responsive to stroke pathology.
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Table 4. Clinical and demographic characteristics of subject sub-populations used for in vitro experiments.

Continuous variables compared with one-way ANOVA (f), categorical variables compared with chi-squared test (χ2)

To explore whether the elevations in sCD163 levels which we observed in AIS potentially play a role in
modulation of the stroke-induced peripheral immune response, we next assessed the relationship between
circulating soluble sCD163 levels and white blood cell counts within the validation cohort AIS group. Plasma
sCD163 levels were significantly negatively associated with absolute lymphocyte counts (Figure 11A), as well
as significantly positively associated with both absolute monocyte counts (Figure 11B) and absolute neutrophil
counts (Figure 11C). Collectively, these results provided in vivo associative evidence which supported our
hypothesis that stroke-induced increases in myeloid-derived circulating sCD163 may contribute to post-stroke
suppression of the adaptive immune system.
Next, we wanted to determine the direct effects of the post-stroke peripheral inflammatory milleu on
ADAM17-mediated sCD163 shedding by peripheral blood innate immune cell populations. To do this, primary
neutrophil and monocyte cultures generated from the peripheral blood of twelve healthy donors were treated
with pooled serum samples derived from a subset of ten AIS patients, ten neurologically asymptomatic controls,
and ten acute stroke mimics which were relatively well matched in terms of clinical and demographic
characteristics (Table 4). Serum incubation was performed in both the presence and absence of the ADAM17
inhibitors TAPI-0 and Marimastat, and cellular ADAM17 activity and sCD14 production were assessed following
treatment.
Neutrophil cultures across all treatment conditions appeared largely phenotypically identical when
visually inspected following treatment (Figure 12A). ADAM17 activity did appear to be elevated in neutrophil
cultures treated with serum obtained from AIS patients relative to those treated with serum obtained from both
neurologically asymptomatic controls and acute stroke mimics, however this increase was not statistically
significant (Figure 12B). Overall, neutrophil cultures appeared to generate relatively little sCD163, although a
limited number of cultures treated with AIS serum did appear to exhibit increased sCD163 production in response
to treatment. This effect was not widespread however, and no statistically significant differences were observed
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Figure 12. Effects of ischemic stroke serum on neutrophil ADAM17-dependant sCD163 production. (A)
Morphology of healthy donor-derived neutrophils following three hours incubation with 10% serum obtained from AIS
patients and control subjects, in either the presence and absence of ADAM17 inhibitors. (B) ADAM17 activity in
neutrophil lysates collected following treatment. (C) Neutrophil-derived sCD163 levels in cell culture supernatants
collected following treatment, presented as the difference in sCD163 levels observed between cell culture
supernatants and serum-supplemented media incubated in the absence of cells. Intergroup comparisons were made
via one-way ANOVA with subsequent Bonferonni post-hoc.

Figure 13. Effects of ischemic stroke serum on monocyte ADAM17-dependant sCD163 production. (A)
Morphology of healthy donor-derived monocytes following three hours incubation with 20% serum obtained from AIS
patients and control subjects, in either the presence and absence of ADAM17 inhibitors. White arrowheads indicate
cytoplasmic vacuoles. (B) ADAM17 activity in monocyte lysates collected following treatment. (C) monocyte-derived
sCD163 levels in cell culture supernatants collected following treatment, presented as the difference in sCD163 levels
observed between cell culture supernatants and serum-supplemented media incubated in the absence of cells.
Intergroup comparisons were made via one-way ANOVA with subsequent Bonferonni post-hoc.

in sCD163 production between cultures treated with AIS serum and those treated with serum from control groups
(Figure 12C). A second independent experiment using pooled serum samples derived from a separate sub-set
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Figure 14. Influence of post-stroke peripheral blood sCD163 levels on the capacity to support lymphocyte
proliferation. (A) Morphology of healthy donor-derived lymphocytes following 72 hours of PHA-stimulated
proliferation in the presence of 20% serum obtained from AIS patients and controls, which was either unmanipulated
in terms of sCD163 levels, or depleted of sCD163 via immunoprecipitation using anti-CD163 monoclonal antibody.
White arrowheads indicate clusters of blasting lymphocytes. (B) BrdU incorporation over the final 24 hours of
treatment. Intergroup comparisons were made via one-way ANOVA with subsequent Bonferonni post-hoc.

of subjects (Supplemental Table 2) yielded similar results (Supplemental Figure 2).
Counter to what was observed in terms of neutrophil cultures, there were striking visual differences
between monocyte cultures treated with serum derived from AIS patients and those treated with serum derived
from control groups. Cultures treated with control serum generally displayed a mix of adherent and semiadherent cells, however several cultures incubated with AIS serum contained large patches of cells which
appeared highly adherent with prominent cytoplasmic vacuoles characteristic of a shift towards a macrophage
phenotype (Figure 13A). ADAM17 activity was significantly elevated in monocytes treated with AIS serum relative
to those treated with serum from both control groups (Figure 13B). Furthermore, supernatants recovered from
cultures treated with AIS serum contained significantly higher concentrations of monocyte-derived sCD163 than
those recovered from cultures treated with serum from either control group, and this effect was largely ablated
by inhibition of ADAM17 (Figure 13C). Once again, similar results were observed in a second independent
experiment (Supplemental Figure 3) using pooled serum samples derived from a separate sub-set of subjects
(Supplemental Table 2). Collectively, these observations demonstrate that soluble factors present in peripheral
circulation following ischemic stroke have the capacity to trigger ADAM17-dependant sCD163 shedding from
peripheral blood monocytes, however likely not from neutrophils.
Lastly, we wanted to determine the direct effect of post-stroke-elevations in circulating sCD163 levels on
the capacity of the peripheral blood to support lymphocyte proliferation. To do this, PHA-stimulated proliferation
of healthy-donor derived lymphocytes was assessed via BrdU incorporation in the presence of pooled serum
obtained from control groups, pooled serum from AIS patients, and pooled serum obtained from AIS patients
which had been depleted of sCD163 by immunoprecipitation (Supplemental Figure 4). Consistent with prior
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reports,52 visual observations suggested decreased proliferative activity in lymphocyte cultures treated with
unmanipulated AIS serum relative to those treated with serum from control groups, as they appeared to contain
smaller and more diffuse clusters of blasting lymphocytes (Figure 14A). However, visual indications suggested
that the inhibitory effect of AIS serum was at least moderately counteracted by the depletion of cCD163 (Figure
14A). In agreement with these visual observations, we observed significantly lower levels of BrDU incporperation
in lymphocytes stimulated in the presence of AIS serum relative to those which were stimulated in the presence
of serum derived from control groups, an effect which was partially ablated as a result of sCD163 depletion
(Figure 14B). A second independent experiment using pooled serum samples derived from a separate sub-set
of subjects (Supplemental Table 2) yielded similar results (Supplemental Figure 5).
Taken together, these results novelly suggest that post-stroke elevation in circulating levels of monocytederived sCD163 can have direct inhibitory effects on the proliferative capacity of lymphocytes, inferring a unique
synergistic mechanism directly linking stroke induced activation of the peripheral innate immune system and
suppression of the peripheral adaptive immune system.
Note: Full manuscript associated with these results can be found in Appendix, Manuscript 3.
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Chapter 4.

Discussion:
The primary objective of this work was to implement a biomarker discovery strategy employing high
throughput transcriptomics in tandem with machine learning analysis to identify patterns of gene expression in
peripheral whole blood with the potential to detect AIS, and to further determine the role of such patterns within
the context of stroke immunopathology. The ten transcriptional markers identified by GA/kNN in our analysis
proved robust in their combined ability to differentiate between AIS patients and controls in both the discovery
cohort and the independent validation cohort; not only did these markers display levels of diagnostic accuracy
which exceed those reported in a majority of previous stroke biomarker studies, they also demonstrated
characteristics which suggest they have the potential to be clinically useful. Furthermore, we were able to discern
that many if not all these ten markers are likely differentially regulated in the peripheral whole blood of AIS
patients as markers of stroke-induced shifts in white blood cell differential. However, our findings did suggest
that one of these ten markers, CD163, may play a role in modulation of stroke-induced peripheral immune
phenotype via a unique mechanism linking the coordinate responses of the innate and adaptive immune
systems.
Machine learning for identification of candidate ischemic stroke biomarkers:
With regards to the countless number peripheral blood biomarker explorations which have been
performed to date,5–9 to our knowledge, only one prior investigation has reported similar levels of diagnostic
accuracy to those which we observed in this study in terms of discriminating between stroke patients and
clinically relevant control populations. Dambinova et al.68 recently reported that plasma levels of brain-derived
NR2 peptide, a degradation product of N-methyl-D-aspartate (NMDA) receptor cleavage, could be used to
differentiate between stroke patients and a combination of acute stroke mimics and neurologically asymptomatic
controls with 92% sensitivity and 96% specificity. However, a majority of blood samples in this prior study were
obtained between 24 and 72 hours post symptom onset, and it is currently unknown if NR2 peptide would exhibit
an equivalent level of diagnostic performance early in the acute phase of care. The ten marker panel identified
in our analysis was tested earlier in the progression of pathology, and thus exhibits an obvious advantage in that
it has the potential to provide actionable diagnostic information at an early enough time point to influence critical
triage decisions which impact outcome.
The ten marker panel identified in our analysis displayed several favorable characteristics which could
make it well suited for identification of ischemic stroke in the acute care setting. Most notably, the pattern of
differential expression we observed between AIS patients and controls appeared to be relatively temporally
stable. This is of clinical relevance from the standpoint that it is well established that acute stroke patients tend
to arrive to the emergency department in two waves, the first within four hours from symptom onset (typically
patients with more severe overt symptoms), and the second more than eight hours from symptom onset (typically
patients with milder symptoms).69 For this reason, a potential diagnostic for identification of acute stroke needs
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to be diagnostically robust across a wide time window with regards to the progression of stroke pathology.
Another diagnostically beneficial characteristic we observed was that the stroke-associated pattern of expression
across these ten markers was positively correlated with the NIHSS. Thus, these markers may have utility in
stratifying injury severity, information which is commonly considered when making decisions regarding the
prescription of interventional treatment.26 These characteristics, along with the fact that we observed levels of
sensitivity and specificity which well exceed those achievable via the tools currently available to clinicians for the
identification of stroke during acute triage, suggest that the ten marker panel identified in our analysis has
legitimate potential for future clinical implementation.
While the findings reported here are exciting, it is important to note that this work was not without
limitations. Of these, the one which had the greatest potential to confound the interpretation of our results was
the fact that AIS patients and neurologically asymptomatic controls in our discovery cohort were not well matched
with regards to several clinical and demographic characteristics; thus, intergroup differences in these factors had
the potential to confound the selection of stroke specific genes in our GA/kNN analysis. To account for this
possible limitation, we utilized a relatively high termination cut-off for optimal solution selection; under these
conditions, a confounding factor would have to be almost ubiquitously present in one group, and nearly
ubiquitously absent in the other, for it to influence the selection of candidate genes. The results of our multiple
regression analysis suggest that this strategy was largely successful, however, they did infer that medication
status may influence the expression of the candidate genes. Despite this, the ten candidate genes were still able
to demonstrate high levels of diagnostic accuracy when discriminating between groups which were better
matched in terms of these factors in the validation cohort.
Furthermore, there were additional limitations regarding the design of this study which would need to be
addressed in future studies in order to move the biomarker panel identified in this investigation closer to clinical
use. The first of these limitations regards the timing of blood sampling. One area in which the panel of biomarkers
identified in our analysis would potentially have the greatest utility is in the pre-hospital setting, however, blood
in our study was sampled at emergency department admission. While few stroke biomarker studies have
sampled blood at as early of a time in AIS progression, blood would be sampled even earlier in the case of prehospital utilization. While our findings did suggest that the differential expression of the ten candidate markers is
relatively temporally stable, blood was sampled from very few patients in under two hours from time of symptom
onset. Thus, it would be encouraging to see in future work that the ten candidate genes exhibit a similar pattern
of differential expression at even earlier time points in AIS progression.
Another limitation of this study regarding translation to pre-hospital use was our method of blood
sampling. Blood was sampled via venipuncture, however venipuncture is rarely performed in the prehospital
setting. Instead, blood sampling is typically performed via finger stick, which yields samples comprised
predominantly of capillary blood. This could be problematic from that standpoint that recent studies have
suggested that gene expression can differ significantly between whole venous and whole capillary blood, 70
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possibly due to differences in cellular composition.71 Thus, for future pre-hospital implementation, it would need
to be determined in future studies that the pattern of differential expression which we observed in peripheral
venous blood across the ten candidate genes is equally observable in capillary blood.
An additional aspect of this study which could be improved upon in future work was the fact that our
analysis only included ischemic stroke patients, and not patients diagnosed as other stroke subtypes such as
intracerebral hemorrhage (ICH) and transient ischemic attack (TIA). Thus, it is currently unclear whether the
pattern of differential expression we observed in this analysis is specific to AIS, or is a general response to brain
injury. While the pattern of expression which was identified here would have clinical utility in either scenario, it is
a distinction which would need to be made prior to clinical use. This, and the aforementioned limitations would
perhaps be best addressed through implementation of a pilot clinical trial in which the expression levels of the
candidate genes are measured in capillary blood samples obtained from consecutive suspected stroke patients
in the pre-hospital setting. Such a study would provide valuable information regarding the true clinical potential
of the gene expression pattern identified in this discovery study; collectively, it would potentially address current
questions regarding the candidate pattern of differential expression regarding its temporal robustness, its
detectability in capillary blood, and its specificity in terms of stroke-subtypes.
Another potential hurdle regarding the clinical implementation of the panel identified in this study is the
fact that it is comprised of transcriptional biomarkers. There is currently no point of care diagnostic platform which
is FDA approved for detection of endogenous human RNA, as almost all point of care technologies which are in
clinical use have been developed for detection of proteins. However, research into rapid detection of nucleic
acids is ongoing, and promising new advances such as those regarding direct RNA nanodetection and
thermoneutral amplification suggest that suitable technologies will be available in the near future.72–74
Furthermore, it is likely that proper clinical validation of the markers identified this discovery study would take
several years, and it is not improbable to think that suitable point of care detection platforms will be close to
clinical use by that time.
Limitations aside, the robustness of our results demonstrate the power of the biomarker discovery
paradigm employed in this investigation. Our findings support the notion that the stroke-induced peripheral
immune response is viable source of biomarkers, and highlight that utility of high-throughput omics and machine
learning techniques for candidate marker selection. While this study was aimed specifically at discovery of
biomarkers for acute detection of stroke, it is likely that a similar approach could be used to identify biomarkers
which address other clinical diagnostic needs within the realm of cerebrovascular disease. With this in mind, we
are currently employing similar strategies to identify candidate biomarkers which could potentially be used to
predict the efficacy of thrombolytic therapy and flag patients who at high risk for post-stroke BBB complications.
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Role of stroke-identifying biomarkers in immunopathology:
Collectively, the relationships we observed with NMLR within the AIS group, along with the strong trend
of lineage-specific expression which we observed on isolated leukocyte populations from healthy donors,
suggest that the pattern of differential expression which we observed across the top 10 genes in whole blood in
AIS likely serves simply as a marker of the shift in white blood cell differential which is known to occur in response
to stroke. While this does not diminish the diagnostic potential of these genes as biomarkers, it suggests that
many of them do not play a substantial mechanistic role in driving stroke immune pathology, as genes which
drive the peripheral immune response are more likely to be transcriptionally differentially regulated at the level
of individual cells. These findings not only provide a mechanistic explanation for the results of our microarray
analysis, but they also provide insights into prior studies by other groups which have analyzed the transcriptome
of peripheral whole blood in stroke.
Two previous studies have used microarray for expression profiling of whole blood in an attempt identify
mechanisms which drive stroke-induced immunopathology.16,18 By extension, our findings suggest that it is
plausible that many of the genes identified as being differentially regulated in these studies exhibit altered
expression in stroke as markers of changes in white blood cell differential as well. This would infer that the
biological mechanisms implied by these studies may in some ways be flawed. To assess this possibility, we
measured the leukocyte sub-population expression levels of three genes identified by these studies as potentially
playing a mechanistic role in driving post stroke immune suppression. Expression levels of ARG1 and NPL were
demonstrated to be upregulated in whole blood in response to stroke in both studies; expectedly, we observed
hundreds to thousands fold higher expression levels of these genes in cells of myeloid origin than in cells of
lymphoid origin (Supplemental Figure 6A, 6B). These studies identified expression levels of CCR7 as being
downregulated in whole blood in response to stroke; expectedly, we observed hundreds fold higher expression
levels on cells of lymphoid origin than on cells of myeloid origin (Supplemental Figure 6C). While not definitively,
these observations provide reason to believe that at least some of the genes suggested by these whole blood
expression profiling studies as being mechanistic drivers of stroke immunopathology exhibit altered expression
in whole blood simply as markers of changes in white blood cell differential, and may not play as mechanistic of
a role as previously suggested. Our findings broadly suggest that the changes in white blood cell differential
which occur in response to stroke makes reliably identifying pathologically relevant genes in whole blood
unrealistic. Future studies which aim to use expression profiling of the peripheral immune system should take
care to avoid this confound by measuring stroke induced changes in isolated leukocyte sub-populations or on
single cells.
CD163 as a potential modulator of the stroke-induced peripheral immune response:
Of the top ten genes identified in our GA/kNN analysis, we felt that CD163 had the greatest potential to
play a dual role not only as a marker of post-stroke white blood cell differential, but also as a mechanistic
modulator of the stroke-induced peripheral immune response. We hypothesized that coordinate increases in the
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number of CD163 expressing innate immune cells and elevations in ADAM17 activity induced by stroke could
drive increases in peripherally circulating levels of sCD163, which could ultimately contribute to suppression of
the adaptive immune system via the known inhibitory effects of sCD163 on lymphocyte activity.
Observations of elevated levels of sCD163 and ADAM17 activity in the peripheral blood of AIS patients,
along with the fact that these elevations in sCD163 were negatively associated with lymphocyte counts, provided
in vivo associative evidence supporting our hypothesis. Furthermore, our in vitro observations suggested that
this stroke-induced increase in circulating sCD16 most likely originates from peripheral blood monocytes, as
serum from AIS patients stimulated ADAM17-dependant production shedding in monocyte cultures obtained
from healthy individuals. Our in vitro observations further suggested that stroke-induced elevations in circulating
sCD163 elicit direct suppressive effects on the adaptive immune system, as depletion of sCD163 from AIS
patient-derived serum was able to partially rescue its capacity to support lymphocyte proliferation. Collectively,
these findings novelly suggest that sCD163 plays a mechanistic role in modulation of peripheral immunity
following AIS, as a factor directly linking innate immune system activation and adaptive immune suppression.
To our knowledge, our results are the first to demonstrate a direct role for the innate immune system in
mediating stroke-induced suppression of the peripheral adaptive immune system. While our results highlighted
sCD163 as a means of such cross-communication, it is likely other innate-derived factors function to mediate
the adaptive immune response to stroke via similar mechanisms. This notion is accentuated by the fact that
complete ablation of sCD163 from stroke-derived serum was not adequate to fully rescue its capacity to support
lymphocyte proliferation, inferring that there are a multitude of other soluble factors present in post-stroke
peripheral circulation which have similar inhibitory effects. While the origins of these factors are inevitably
diverse, it is likely that some arise via a similar mechanism as sCD163, as biological mechanisms are often
redundant.75 Interesting from this regard is cluster of differentiation 14 (CD14), a membrane-bound pattern
recognition receptor which is largely exclusive to the innate immune system.76,77 Much like CD163, CD14 can be
shed via an MMP-dependent mechanism to generate a soluble protein (sCD14) which has been shown to directly
interact with lymphocytes and exert suppressive effects.78,79 Preliminary results from our laboratory suggest that
circulating levels of sCD14 are also elevated in response to stroke, and further exploration may reveal that sCD14
plays similar role as sCD163 in modulation of the peripheral adaptive immune response.
While this study identified a clear role for sCD163 in stroke immunopathology in terms of its end-action,
our experiments did not look to identify the soluble factors present in peripheral circulation following stroke which
are responsible for triggering the shedding of CD163 from monocytes. It is plausible to believe that this
phenomenon is likely driven by a synergistic combination of stroke-induced DAMs, cytokines, and hormones, as
members of the aforementioned families of factors are known to stimulate CD163 shedding. Notable from this
standpoint is extracellular hemoglobin, a DAM which has been previously demonstrated as being acutely
elevated in peripheral circulation following stroke as a result of intravascular and extravascular hemolysis.80 Free
hemoglobin has been characterized as a potent inducer of CD163 shedding,81 and thus, may help drive
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production of sCD163 in response to stroke. Along similar lines, levels of interleukin-6, cortisol, and reactive
oxygen species, are all known to be elevated acutely in stroke pathology,66,82,83 and all have been shown to
promote sCD163 production.84,85 Further exploration into these and other potential molecular signals which may
trigger sCD13 generation within the context of stroke could not only provide a more complete picture of the
mechanisms identified in this study, but a better understanding of post-stroke adaptive immune suppression as
a whole, as the factors which drive post-stroke sCD163 production likely exert suppressive effects on the
peripheral immune system via multiple parallel mechanisms.
While our findings are exciting, it is important to note that potentially confounding the interpretation of our
results is the fact that elevations in sCD163 have been previously reported in atherosclerosis as a result of
excessive intravascular macrophage activity within atherosclerotic plaques.86 As atherosclerosis is closely linked
with stroke as one of its primary pathogenic drivers,87 it leaves open the possibility that our results were
atherosclerosis driven, and not by the acute event of stroke itself. However, we find this scenario unlikely, as
subjects in our control groups were well matched with AIS patients in terms of the prevalence of cardiovascular
disease risk factors associated with atherosclerosis. Supporting our notion that the elevations in sCD163 which
we observed in AIS were a direct result of the stroke-induced neurological insult is the fact that it has recently
been reported that levels of macrophage-derived sCD163 are elevated in the cerebrospinal fluid (CSF) of
pediatric traumatic brain injury (TBI) patients,88 providing concurrent evidence that cerebral trauma has the
capacity to directly trigger increased sCD163 production. Furthermore, our findings, taken with theirs, suggest
the possibility that stroke-induced elevations in sCD163 may not only modulation adaptive immune activity in the
periphery, but could also serve a similar function within the lesion in terms of adaptive cellular infiltrates.
From a broader perspective, our findings are intriguing as they demonstrate a departure from the
compartmentalized view of stroke immunopathology. While there are some exceptions, research regarding
stroke immunopathology has long and too often treated the adaptive and innate immune responses as
independent entities, however our results and those of select others suggest that these responses are likely
synergistically linked via direct mechanisms. This realization is of utmost importance with regards to the current
push towards the development of novel stroke therapeutics which target the peripheral immune system.
Currently, experimental immune therapies are being developed which largely aim to improve stroke outcome via
one of two often discrete avenues: either by inhibiting the acute innate immune response to stroke as means of
limiting excessive tissue damage and mitigating the risk of negative secondary cerebrovascular events such as
edema and hemorrhagic transformation,89–91 or by post-acutely stimulating the peripheral adaptive immune
system as a means of limiting the risk of complications induced by post-stroke infection.92–95 However,
immunotherapeutics proposed along this line of thinking often fail to account the possible interplay between the
adaptive and innate immune systems, and the potential repercussions that could stem from modulating one
response without consideration for the other.
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A perfect example in this regard is the fact that ADAM17 inhibitors are often cited as a potential stroke
therapeutic under the premise that they could ultimately limit excessive innate-driven inflammation and its
associated complications via a reduction in TNFα production.96–99 However, our results clearly demonstrate that
inhibition of ADAM17 within the innate immune system could directly interfere with mechanisms which act to
suppress the adaptive immune system, an unintended effect which could put patients at elevated risk for the
development of long-term autoimmune complications associated with loss of CNS self-tolerance. Such an
example highlights the necessity for a global view regarding the peripheral immune system in terms of the
development of novel stroke immunotherapeutics. Unfortunately, therapeutic design from such a perspective is
currently unrealistic, as the mechanisms which drive the stroke-induced peripheral immune response, particularly
that of the adaptive immune system, are still largely unknown. This current gap in knowledge may underlie the
reality that stroke immunotherapeutics have thus-far been largely unsuccessful.47 Further future work which aims
to characterize the peripheral immune response to stroke and its underlying mechanisms from a panoptic
systems biology approach, preferably within human-centric models, would likely generate the foundational basis
for the development of stroke immunotherapeudics with higher chances for clinical success.
Conclusions:
Taken as a whole, the results of this work demonstrate that a highly accurate RNA-based companion
diagnostic for AIS is plausible using a relatively small number of markers, and also highlight the potential power
of machine learning approaches for biomarker discovery in the realm of CVD. The ten transcriptional biomarkers
identified in our GA/kNN analysis displayed levels of diagnostic performance which well exceed those reported
in a majority of previous stroke biomarker investigations, as well as several characteristics which suggest they
may have true clinical utility for identification of ischemic stroke during the acute phase of care; due to the robust
nature of these findings, these markers warrant further evaluation to determine their true diagnostic efficacy in
the clinical setting. While our results suggested that a majority of these ten markers likely do not play a role as
mechanistic drivers of the stroke immunopathology, they did imply that one of them, CD163, may play a role in
modulation of stroke-induced peripheral immune phenotype via a unique mechanism linking the coordinate
responses of the innate and adaptive immune systems. From this regard, our results highlight a need for future
research which examines the interplay between the innate and adaptive peripheral immune responses within
the context of stroke, as such research could provide a better understanding of stroke pathology as a whole, and
lead to the development of more effective immunotherapeutics.
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Chapter 5.

Experimental procedures:
Discovery cohort patients:
Discovery cohort AIS patients and neurologically asymptomatic controls were recruited at Suburban
Hospital, Bethesda, MD, which serves an upper-class metro area bordering Washington DC. AIS cases were of
mixed etiology, and diagnosis was confirmed by MRI according to the established criteria for diagnosis of acute
ischemic cerebrovascular syndrome (AICS).100 The median time from symptom onset to blood draw was 5.3
hours, as determined by the time the patient was last known to be free of AIS symptoms. In the case of patients
who received thrombolytic therapy, blood samples were collected prior to the administration of recombinant
tissue plasminogen activator (rtPA). Injury severity was determined according to NIHSS at the time of blood
draw. Control subjects were deemed neurologically normal by a trained neurologist at the time of enrolment.
Demographic information was collected from either the subject or significant other by a trained clinician. All
procedures were approved by the institutional review boards of the National Institute of Neurological
Disorders/National Institute on Aging at National Institutes of Health and Suburban Hospital. Written informed
consent was obtained from all subjects or their authorized representatives prior to any study procedures.
Validation cohort patients:
Validation cohort AIS patients, acute stroke mimics, and neurologically asymptomatic controls were
recruited at Ruby Memorial Hospital, Morgantown, WV, which serves an impoverished rural region of West
Virginia which displays some of the highest CVD rates in the nation.1 As with the discovery cohort, AIS cases
were of mixed etiology, and diagnosis was confirmed via neuroradiological imaging. Patients admitted to the
emergency department as suspected strokes based on the overt presentation of stroke-like symptoms, but
receiving a negative diagnosis for stroke upon imaging according to the established AICS diagnostic criteria
were identified as acute stroke mimics.100 Discharge diagnoses of stroke mimics included cases of seizures,
complex migraines, and other conditions which induce neurological symptoms such as hypertensive
encephalopathy. The median time from symptom onset to blood draw was 4.6 hours and all blood was sampled
before the administration of rtPA. Assessment of injury severity, screening of neurologically asymptomatic
controls, and collection of demographic information was performed in an identical manner as in the discovery
cohort. All procedures were approved by the institutional review boards of West Virginia University and Ruby
Memorial Hospital. Written informed consent was obtained from all subjects or their authorized representatives
prior to study procedures.
Neuroradiological imaging:
Neuroradiological imaging was performed using either MRI or CT within 24 hours of symptom onset. CT
imaging was performed on either a Toshiba Aquilion 64 or Toshiba Aquilion 320 scanner (5 mm slices acquired
at 120 KVp, 250 mA). MRI imaging was performed using either a Siemens Aera or Siemens Verio scanner (5
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mm slices, 5 mm inter-slice gap, acquired via diffusion-weighted echoplanar imaging with a B-factor of 1000
s/mm2). The BrainLAB iPlan Neuroradiology software package (BrainLAB, Westchester, Ill) was used to calculate
infarct volume via manual tracing as previously described,101 and all infarct volume calculations were verified by
an experienced neuroradiologist.
Blood collection:
Parallel peripheral intravenous whole blood samples were collected from subjects via PAXgene RNA
tubes (Qiagen, Valencia, CA), K2EDTA Vacutainers (Becton Dickenson, Franklin Lakes, NJ), and serum
separator tubes (Becton Dickenson). PAXgene RNA tubes were frozen immediately and stored at -80ºC until
RNA extraction. K2EDTA tubes were stored at room temperature until white blood cell differential (less than 30
minutes), plasma isolation (less than 30 minutes), or leukocyte isolation (performed immediately). Serum
separator tubes were stored at room temperature until serum isolation (less than 30 minutes).
Isolation of serum and plasma:
For plasma isolation, EDTA-treated blood was spun at 2,000*g for 10 minutes to sediment hemocytes.
Plasma was collected for ELISA, and the total hemocyte fraction was retained for subsequent protein extraction.
Plasma was additionally spun at 10,000*g for 10 minutes to remove any residual blood cells or debris. For serum
isolation, serum separator tubes were incubated at room temperature for a minimum of 15 minutes to allow for
clot formation, and subsequently spun at 2,000*g for 10 minutes to sediment the resulting thrombus. Resultant
samples were stored at -80ºC until analysis.
Isolation of leukocyte subpopulations for RNA analysis:
Leukocytes were isolated from healthy donor-derived EDTA-treated blood via immuno-magnetic negative
selection (EasySep Direct, StemCell Technologies). Neutrophils, monocytes, CD4+ T-lymphocytes, CD8+ Tlymphocytes, B-lymphocytes, and NK-cells were isolated from 4 mLs of blood per population according to
manufacture recommended protocols. Isolated cells were rinsed once in PBS and lysed in Qiagen buffer RLT
containing beta-mercaptoethanol (BME), flash frozen in liquid nitrogen, and stored at -80 until RNA extraction.
RNA extraction:
Whole blood RNA was extracted from PAXgene tubes via the PreAnalytiX PAXgene blood RNA kit
(Qiagen) and automated using the QIAcube system (Qiagen). RNA was isolated from leukocyte lysates via the
RNeasy Micro kit (Qiagen). Quantity and purity of isolated RNA was determined via spectrophotometry
(NanoDrop, Thermo Scientific, Waltham, MA). Quality of RNA was confirmed by chip capillary electrophoresis
(Agilent 2100 Bioanalyzer, Agilent Technologies, Santa Clara, CA).
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RNA amplification and microarray:
RNA was amplified and biotinylated using the TotalPrep RNA amplification kit (Applied Biosystems,
Grand Island, NY). Samples were hybridized to HumanRef-8 expression bead chips (Illumina, San Diego, CA)
containing 25,000 unique probes and scanned using the Illumina BeadStation. Raw probe intensities were
background subtracted, quantile normalized, and then summarized at the gene level using Illumina
GenomeStudio. Sample labeling, hybridization, and scanning were performed per standard Illumina protocols.
Raw data are assessable through the National Center for Biotechnology Information (NCBI) Gene Expression
Omnibus (GEO) via accession number GSE16561.
GA/kNN analysis:
Normalized microarray data were filtered based on absolute fold difference between stroke and control;
genes exhibiting a greater than 1.7 absolute fold difference in expression between AIS and control were retained
for analysis. Filtered gene expression data were z-transformed and GA/kNN analysis was performed using C
source code developed by Li et al.,23 compiled in Linux Mint. Two-thousand near-optimal solutions were collected
per sample using five nearest neighbors, majority rule, a chromosome length of five, and a termination cutoff of
0.97. Leave one out cross validation was performed using the top 50 ranked genes. The top 50 genes were
tested against random gene combinations which were selected using the R sample() function (R 2.14, R Project
for Statistical Computing).
Quantitative reverse transcription PCR:
cDNA was generated from purified RNA using the Applied Biosystems high capacity reverse transcription
kit. For qPCR, target sequences were amplified from 10 ng of cDNA input using sequence specific primers
(Supplemental Table 3) and detected via SYBR green (PowerSYBR, Thermo-Fisher) on the RotorGeneQ
(Qiagen). Raw amplification plots were background corrected and CT values were generated via the
RotorGeneQ software package. All reactions were performed in triplicate. Transcripts of B2M, PPIB, and ACTB
were amplified as references and normalization was performed using the NORMAgene data-driven normalization
algorithm (validation of this normalization strategy can be found in Appendix, Manuscript 7).102
White blood cell differential and NMLR:
Complete blood count was obtained from EDTA-treated blood via combined optical flow cytometry and
cellular impedance using an automated clinical hematology analyzer (Cell-Dyn, Abbott Diagnostics, Santa
Clara, CA). NMLR was calculated as the geometric mean of absolute neutrophil and absolute monocyte count
divided by absolute lymphocyte count (NMLR = sqrt[ neutrophil count * monocyte count ] / lymphocyte count).
Isolation of primary leukocytes for cell culture:
Starting with 30 mLs of healthy donor-derived EDTA-treated blood, peripheral blood mononuclear cells
(PBMCs) were separated from polymorphonuclear cells (PMNs) and RBCs via centrifugation over a
35

polysaccharide-sodium diatrizoate density gradient (Lymphoprep, 1.077 g/mL, StemCell Technologies) for 30
minutes at 400*g. Resultant interphase PBMC fractions were collected, resuspended in RPMI 1640 (Life
Technologies, Grand Island, NY) containing 10% autologous serum, separated into two aliquots, and set aside
at room temperature. Pelleted PMN/RBCs were immediately placed on ice for PMN enrichment via RBC lysis
induced by two 5 minute incubations with a 1:10 volume of ice cold ammonium chloride (ACK) buffer. The
resultant PMNs were rinsed in ice cold PBS, counted via automated cytometer (Cellmeter X1, Nexcelom
Bioscience, Lawrence, MA), and immediately plated for experiments.
Following PNM isolation, monocytes were further enriched from one aliquot of PBMCs via a second round
of density gradient centrifugation as described by Menck et al.103 Briefly, PBMC suspensions were layered over
an iso-osmotic 46% Percoll (1.131 g/mL, Sigma Aldrich) solution prepared in RPMI 1640 containing 10%
autologous serum and centrifuged at 500*g for 30 minutes. Monocytes were collected from the resultant
interphase, rinsed in PBS, counted, and immediately plated for experiments.
Following PMN and monocyte isolation, the remaining aliquot of PBMCs was rinsed in PBS and seeded
in T75 flasks for lymphocyte expansion. Lymphocytes were expanded for 72 hours under standard mammalian
cell culture conditions in a growth media comprised of RPMI 1640 containing 2% PHA-M (Gibco, Grand Island,
NY), 2 mM L-Alanyl-Glutamine (GlutaMAX, Gibco), 25 mM HEPES (Gibco), 50 uM BME (Gibco), and 1%
antibiotic antimycotic (Gibco), supplemented with 10% autologous serum. Following expansion, actively
proliferating lymphocytes were rinsed in PBS, counted, and plated for experiments.
Neutrophil culture:
Neutrophils from healthy donors were seeded in 12-well plates at a density of 7.5*105 cells per well in
250 uL of RPMI 1640 containing 10% patient serum along with either Marimastat (10 uM, Sigma Aldrich, StLouis, MO), TAPI-0 (10 uM, Sigma Aldrich), or vehicle (DMSO, Fisher Scientific). Following three hours of
incubation under standard mammalian culture conditions, cells were lysed in NP40 lysis buffer (Life
Technologies) and cellular ADAM17 activity was assessed via enzyme activity assay. Cell culture supernatants
were collected and concentrations of sCD163 were quantified via ELISA; levels of neutrophil-derived sCD163
were determined by subtracting the concentration of sCD163 in media incubated without cells from the
concentrations of sCD163 observed in cell culture supernatants.
Monocyte culture:
Monocytes from healthy donors were seeded in 12-well plates at a density of 1*106 cells per well in 250
uL of RPMI 1640 containing 20% patient serum along with either Marimastat (10 uM), TAPI-0 (10 uM), or vehicle
(DMSO). Following three hours of incubation under standard mammalian culture conditions, cells were lysed in
NP40 lysis buffer and cellular ADAM17 activity was assessed via enzyme activity assay. Cell culture
supernatants were collected and concentrations of sCD163 were quantified via ELISA; levels of monocytes36

derived sCD163 were determined by subtracting the concentration of sCD163 in media incubated without cells
from the concentrations of sCD163 observed in cell culture supernatants.
sCD163 depletion from human serum:
sCD163 was depleted from pooled serum samples via immunoprecipitation using biotinylated goat
polyclonal antibody raised against the extracellular region of CD163 (BAF1607, R&D Systems, Minneapolis,
MN). Biotinylated normal goat IgG (BAF108, R&D Systems) was used as an immunoprecipitation control.
Immunoglobulins were conjugated to polymer-coated superparamagnetic beads (Dynabeads Streptavidin T1,
Thermo Fisher, Waltham MA) at a ratio of 40 ug of immunoglobulins per 1 mg of beads. For immunoprecipitation,
5 mL of pooled serum was precleared with 2.5 mg of unconjugated beads, and then incubated with 2.5 mg of
conjugated beads for 12 hours at 4ºC. Beads were subsequently separated from serum samples via multiple
rounds of magnetic separation. Following immunoprecipitation, pooled serum was filtered at 14 microns to
remove potential microbial contaminants prior to cell culture. Depletion of sCD163 was subsequently confirmed
via ELISA (Supplemental Figure 4).
Lymphocyte proliferation assay:
Expanded lymphocytes from healthy donors were seeded in 48 well plates at 5*104 cell per well in 200
uL growth media supplemented 20% pooled patient serum. Following 48 hours of culture, BrdU (Roche Life
Sciences, Indianapolis, IN) was added to cultures at a final concentration of 20 uM. After allowing for 24 hours
for BrdU incorporation, lymphocytes were adhered via centrifugation and fixed for BrdU quantification.
Incorporated BrdU was quantified via colorimetric ELISA (Roche Life Sciences) per manufacture instructions.
sCD163 ELISA:
sCD163 was measured in plasma samples and cell culture supernatants using a commercially available
ELISA assay (RAB0082, Sigma-Aldrich). Plasma samples were diluted 1:50, neutrophil cell culture supernatants
were diluted 1:5, and monocyte cultures were diluted 1:10 prior to analysis. Due to the potential confound of
hemolysis on concentrations of leukocyte derived analyites, plasma samples were screened for hemolysis prior
to ELISA. Plasma absorbance was measured at 385 and 414 nm via spectrophotometry (NanoDrop, Thermo
Scientific, Waltham, MA) and used to calculate a hemolysis score as described by Appierto et. al.104 Hemoglobindepleted plasma (HemogloBind, Biotech Support Group, Monmouth Junction, NJ) spiked with serial dilutions of
sonicated red blood cells were used as a positive control. Plasma samples with detectable hemolysis were
excluded from analysis.
ADAM17 activity assay:
Total hemocyte fractions were thawed, mixed with NP-40 lysis buffer (Thermo Fisher) at a 1 to 1 ratio,
and depleted of hemoglobin via the HemogloBind hemoglobin removal kit (Biotech Support Group, Monmouth
Junction, NJ) as described by Park et al.105 Protein concentrations of hemoglobin-depleted total hemocyte
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lysates and cell culture lysates were determined via DC-protein assay (Bio-Rad, Hercules, CA). ADAM17 activity
was measured in 25 ug of total hemocyte lysate, or 10 ug of cell culture lysate, via the InnoZyme TACE activity
kit (EMD Millipore, Temecula, CA) per manufacture instructions. Due to the reversible nature of ADAM17
inhibition by both marimastat and TAPI-0, experimental concentrations of drug were maintained in assay buffers
when testing samples from inhibitor-treated conditions.
Phase Contrast Microscopy:
Phase contrast images of primary leukocyte cultures were obtained from an AxioObserver inverted
microscope (Ziess, Thornwood, NY) equipped with a AxioCam mR5 digital camera (Ziess) using the AxioVision
imaging software suite (Ziess). Scale bars were generated via imaging of a 0.07-1.50 mm scale calibration slide
(Motic, Richmond, BC, CA).
Statistical analysis:
Parametric statistical analysis was performed using SPSS (IBM, Chicago, Ill) in combination with R 2.14
via the SPSS R integration plug-in. Chi-squared tests were used for comparison of dichotomous variables.
Student t-tests or one-way ANOVA were used for comparison of continuous variables. Spearman’s rho was used
to assess the strength of correlational relationships. Multiple regression analysis and subsequent variance
decomposition was performed using the relaimpo R package.53 Penalized logistic regression was performed
using the logistf R package.106 The level of significance was established at 0.05 for all parametric statistical
testing. In the cases of multiple comparisons, p-values were adjusted using Holm’s Bonferonni method.107
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Chapter 7.

Supplemental data:

Supplemental Table 1. Influence of potentially confounding clinical and demographic characteristics on the
predictive power of the top ten genes identified by GA/kNN. Firth’s penalized logistic regression was performed
with stroke as the dependent variable and composite RNA expression, age, anticoagulant status, hypertension,
antihypertension medication status, dyslipidemia, history of myocardial infarction, and history of atrial fibrillation as
regressors. In the resultant model, composite RNA expression remained a highly significant predictor of stroke after
considering all other regressors. Furthermore, none of the potentially confounding factors were significant predictors
of stroke in the model.

Supplemental Figure 1. Relationships between post-stroke peripheral blood cellular ADAM17 activity and
plasma sCD163 levels and infarct volume. (A) Relationship between peripheral blood cellular ADAM17 activity
and infarct volume within the validation cohort AIS group. (B) Relationship between plasma sCD163 levels and infarct
volume within the validation cohort AIS group. Strength of correlational relationships were tested via Spearman’s
rho.
Supplemental Table 2. Clinical and demographic characteristics of subject sub-populations used for
independent replicate in vitro experiments.
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Supplemental Figure 2. Effects of ischemic stroke serum on neutrophil ADAM17-dependant sCD163
production in an independent replicate experiment. (A) ADAM17 activity in healthy-donor neutrophil lysates
collected following three hours incubation with 10% serum obtained from AIS patients and control subjects, in either
the presence and absence of ADAM17 inhibitors. (B) Neutrophil-derived sCD163 levels in cell culture supernatants
collected following treatment, presented as the difference in sCD163 levels observed between cell culture
supernatants and serum-supplemented media incubated in the absence of cells. Intergroup comparisons were made
via one-way ANOVA with subsequent Bonferonni post-hoc.

Supplemental Figure 3. Effects of ischemic stroke serum on monocyte ADAM17-dependant sCD163
production in an independent replicate experiment. (A) ADAM17 activity in healthy-donor monocyte lysates
collected following three hours incubation with 10% serum obtained from AIS patients and control subjects, in either
the presence and absence of ADAM17 inhibitors. (B) Monocyte-derived sCD163 levels in cell culture supernatants
collected following treatment, presented as the difference in sCD163 levels observed between cell culture
supernatants and serum-supplemented media incubated in the absence of cells. Intergroup comparisons were made
via one-way ANOVA with subsequent Bonferonni post-hoc.
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Supplemental Figure 4. Confirmation of serum sCD163 depletion using immunoprecipitation. (A)
Concentrations of sCD163 in pooled serum samples obtained from validation cohort AIS patients and controls
measured with ELISA following immunoprecipitation via either anti-CD163 polyclonal antibody or isotype control
immunoglobulin.

Supplemental Figure 5. Influence of post-stroke peripheral blood sCD163 levels on the capacity to support
lymphocyte proliferation in an independent replicate experiment. (A) BrdU incorporation in healthy donor-derived
lymphocytes over the final 24 of 72 hours PHA-stimulated proliferation in the presence of 20% serum obtained from
AIS patients and controls, which was either unmanipulated in terms of sCD163 levels, or depleted of sCD163 via
immunoprecipitation using anti-CD163 monoclonal antibody.
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Supplemental Figure 6. Cell population-specific expression levels of genes highly cited as being potential
drivers of stroke immunopathology based on the finding of prior stroke microarray investigations
performed in whole blood. Expression levels of (A) NPL, (B) ARG1, and (C) CCR7 in peripheral whole blood
and on isolated leukocyte populations obtained from one male and two female healthy donors. Expression levels
are presented as fold change relative to the population of lowest expression, and were statistically compared via
one-way ANOVA.
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Supplemental Table 3. Primers and thermocycling conditions used for qRT-PCR.

49

Appendix.

Associated manuscripts (3)

50

Manuscript 1:

Machine learning approach identifies a pattern of gene expression in peripheral blood which
can accurately detect ischemic stroke.
Grant C. O’Connell, MS1,2,#; Ashley B. Petrone, PhD1; Madison B. Treadway, BSc3; Connie S. Tennant, RN1;
Noelle Lucke-Wold, RN1; Paul D. Chantler, PhD4,5; Taura L. Barr, RN, PhD6,#

Center for Basic and Translational Stroke Research, Robert C. Byrd Health Sciences Center, West Virginia
University, Morgantown, West Virginia
1

Department of Pharmaceutical Sciences, School of Pharmacy, West Virginia University, Morgantown, WV

2

Department of Biology, Eberly College of Arts and Sciences, West Virginia University, Morgantown, WV

3

Center for Cardiovascular and Respiratory Sciences, Robert C. Byrd Health Sciences Center, West Virginia
University, Morgantown, West Virginia
4

Division of Exercise Physiology, School of Medicine, West Virginia University, Morgantown, West Virginia

5

CereDx Incorporated, Morgantown, WV

6

Co-corresponding authors:

#

Taura L. Barr
CereDx Incorporated
Blanchette Rockefeller Neurosciences Institute
Eight Medical Center Drive
Morgantown, WV 26505
Phone: 304-825-3131
Email: tbarr@ceredx.com
Grant C. O’Connell
West Virginia University
Robert C. Byrd Health Sciences Center
One Medical Center Drive
Morgantown, WV 26505
Phone: 920-707-0458
Email: goconnell.wvu@gmail.com
Word Count (with references): 7,396
Tables: 2
Figures: 5
Supplemental Materials: 4
Running Head: Machine learning for stroke biomarker discovery.
Keywords: Biomarkers; Cerebrovascular Disease; Cardiovascular Disease; Pattern Recognition; Immune
System, Systems Biology

51

Abstract:
Early and accurate diagnosis of stroke improves the probability of positive outcome. The objective of this
study was to identify a pattern of gene expression in peripheral blood which could potentially be optimized to
expedite the diagnosis of acute ischemic stroke (AIS). A discovery cohort was recruited comprised of 39 AIS
patients and 24 neurologically asymptomatic controls. Peripheral blood was sampled at emergency department
admission, and genome-wide expression profiling was performed via microarray. A machine learning technique
known genetic algorithm k-nearest neighbors (GA/kNN) was then used to identify a pattern of gene expression
which could optimally discriminate between groups. This pattern of expression was then assessed via qRT-PCR
in an independent validation cohort, where it was evaluated for its ability to discriminate between an additional
39 AIS patients and 30 neurologically asymptomatic controls, as well as 20 acute stroke mimics. GA/kNN
identified ten genes (ANTXR2, STK3, PDK4, CD163, MAL, GRAP, ID3, CTSZ, KIF1B, and PLXDC2) whose
coordinate pattern of expression was able to identify 98.4% of discovery cohort subjects correctly (97.4%
sensitive, 100% specific). In the validation cohort, the expression levels of the same ten genes were able to
identify 95.6% of subjects correctly when comparing AIS patients to asymptomatic controls (92.3% sensitive,
100% specific), and 94.9% of subjects correctly when comparing AIS patients to stroke mimics (97.4% sensitive,
90.0% specific). The transcriptional pattern identified in this study shows strong diagnostic potential, and
warrants further evaluation to determine its true clinical efficacy.
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Introduction:
Stroke is currently the leading cause of disability and fifth leading cause of death in the United States.1 It
is well established that early and accurate diagnosis improves outcome by increasing the probability of
successful intervention,2,3 however, the diagnostic tools currently available to clinicians for the identification of
stroke have significant limitations.
While neuroradiological imaging is the gold standard for diagnosis of stroke,4 it is inaccessible in the field
and at the initial point of contact in emergency departments. Furthermore, such imaging techniques are often
not immediately available in hospitals without dedicated stroke centers, such as smaller facilities and those which
serve rural areas.5 As a result, crucial decisions regarding the triage of potential strokes by emergency
department staff and emergency medical technicians are based on the assessment of overt patient symptoms
using stroke recognition and severity scales such as the Cincinnati prehospital stroke scale (CPSS) and National
Institutes of Health stroke scale (NIHSS).4 In the hospital setting, the ability to identify stroke with such
assessments is highly inconsistent, with an estimated sensitivity ranging from 44-85%, and specificity ranging
between 64-98%.6 The sensitivity and specificity of these assessments is even lower in the pre-hospital setting,7
where the ability to quickly identify stroke facilitates the transfer of patients to stroke ready hospitals, increasing
the chances of appropriate treatment and positive outcome.8 Due to these current limitations, a rapidly
measurable blood-based biomarker panel could be invaluable in informing pre-hospital and in-hospital decisions
early in the acute phase of care, and could ultimately expedite access to interventional treatment.9
As a result, there has been a substantial push for the identification of stroke-associated peripheral blood
biomarkers. The earliest stroke biomarker studies focused on the peripheral blood proteome, and countless
protein-based biomarker panels have been evaluated to date. While a handful of these protein-based panels
have demonstrated a strong ability to differentiate between stroke patients and healthy controls lacking the
presence of cardiovascular disease (CVD) risk factors, a majority have failed to achieve specificities and
sensitivities approaching 90% when tested against clinically relevant control groups.9–13 More recently, the
peripheral blood transcriptome has emerged as a potential source of stroke biomarkers, as preliminary reports
have suggested that gene expression in the peripheral immune system is highly responsive to ischemic brain
injury.14–16 Most notably, Tang et al.16,17 identified a panel of 18 genes whose expression levels demonstrated
the ability to discriminate between acute ischemic stroke (AIS) patients and healthy controls with 93.5%
sensitivity and 89.5% specificity using combined expression data generated from three blood draws obtained
over the first 24 hours of hospitalization. While the necessity to obtain multiple blood samples limited this
biomarker panel with regards to acute stroke triage, this work provided proof of principle that stroke-induced
transcriptional changes in the peripheral immune system could be used to identify stroke with relatively high
levels of accuracy. Thus, it is plausible that implementation of a robust biomarker discovery approach could
identify transcriptional stroke markers with the potential to be diagnostically useful during the acute phase of
care.
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Analysis of high-dimensional gene expression data using a pattern recognition approach known as
genetic algorithm k-nearest neighbors (GA/kNN) has been successfully used in a small number of cancer studies
to identify diagnostically relevant biomarker panels with strong discriminatory ability.18–20 The GA/kNN approach
combines a powerful search heuristic, GA, with a non-parametric classification method, kNN. In GA/kNN
analysis, a small combination of genes (referred to as a chromosome) is generated by random selection from
the total pool of gene expression data (Supplemental Figure 1A). The ability of this randomly generated
chromosome to discriminate between sample classes is then evaluated using kNN. In this evaluation, each
sample is plotted as a vector in a multi-dimensional feature space where the coordinates of the vector are
comprised of the expression levels of the genes of the chromosome. The class of each sample is then predicted
based on the majority class of the nearest neighbors, or other samples which lie closest in Euclidian distance
within the feature space (Supplemental Figure 1B). The ability of the chromosome to discriminate between
classes is quantified as a fitness score, or the proportion of samples which the chromosome is correctly able to
classify. A termination cutoff (minimum proportion of correct classifications) determines the level of fitness
required to pass evaluation. A chromosome which passes kNN evaluation is labeled as a near-optimal solution
and recorded, while a chromosome which fails undergoes repeated cycles of mutation and re-evaluation until a
near optimal solution is reached (Supplemental Figure 1A). This entire search paradigm is performed multiple
times (typically hundreds of thousands) to generate a heterogeneous pool of near-optimal solutions
(Supplemental Figure 1C). The discriminatory ability of each gene is then ranked according to the number of
times it appears in the near-optimal solution pool (Supplemental Figure 1D), and the collective discriminatory
ability of the top ranked genes can then be tested via kNN in a leave one out cross validation (Supplemental
Figure 1E). This approach has been utilized to generate biomarker panels capable of optimally discriminating
between cancerous and non-cancerous colon biopsies,20 primary and metastatic melanoma tumors,18 as well as
between B-cell lymphoma sub-types,19 all with accuracies ranging between 95 and 100%.
While GA/kNN has proven robust in several applications in the field of cancer, it has yet to be utilized for
biomarker discovery in the realm of cardiovascular disease (CVD). In this study, we applied the GA/kNN
approach to analyze peripheral blood gene expression data generated via microarray to identify transcriptional
patterns which could potentially be optimized for the detection of AIS in the acute phase of care.
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Results:
Discovery Cohort:
In order to identify potential transcriptional biomarkers for the identification of AIS, we first recruited a
discovery cohort comprised of 39 AIS patients and 24 neurologically asymptomatic controls. In terms of
demographic and clinical characteristics, AIS patients were older than controls, and displayed a higher
prevalence of CVD risk factors such as hypertension and dyslipidemia (Table 1). Furthermore, AIS patients
displayed a more substantial history of cardiac conditions such as myocardial infarction and atrial fibrillation, and
higher proportion of AIS patients reported as currently taking antihypertensives and anticoagulants.
Peripheral whole blood was sampled from patients at emergency department admission, and genomewide expression profiling was performed via microarray. Gene expression data were subjected to GA/kNN
analysis, and genes were ranked based on the ability of their expression levels to discriminate between AIS
patients and controls, according to the number of times they were selected as part of a near-optimal solution
(Figure 1A). The expression levels of top 50 genes identified by GA/kNN displayed a strong ability to discriminate
between groups using kNN in leave one out cross validation; a combination of just the top ten ranking genes
(ANTXR2, STK3, PDK4, CD163, MAL, GRAP, ID3, CTSZ, KIF1B, and PLXDC2) were able to classify 98.4% of
subjects in the discovery cohort correctly with a sensitivity of 97.4% and specificity of 100% (Figure 1B).
In order to evaluate the robustness of our GA/kNN analysis in terms of its ability to select optimally
discriminative genes, we compared the ability of the expression levels of top 50 genes selected by GA/kNN to
differentiate between stroke patients and controls to that of genes selected at random. Specifically, we compared
the accuracy of GA/kNN-selected genes to the accuracy of 50 sets of 50 genes randomly generated from the
total pool of gene expression data, as well to the accuracy of 50 sets of 50 genes randomly selected from a subpool of genes which displayed greater than 1.7 fold differential regulation between groups. The top genes
selected by GA/kNN performed significantly better than genes selected at random genome-wide, as well as
significantly better than genes selected at random from those which were differentially regulated greater than
1.7 fold (Figure 1C). Collectively, the results of this analysis, in combination with the levels of accuracy observed,
suggest that our biomarker discovery strategy was effective at selecting genes with optimal diagnostic potential
in terms of the subjects of the discovery cohort. Because the use of genes beyond the top ten did not appear to
improve overall accuracy (Figure 1B), and displayed diminishing diagnostic robustness relative to genes selected
at random (Figure 1C), we chose to focus on only the top ten genes for the remainder of our analysis.
When comparing the peripheral blood expression levels of the top ten genes between AIS patients and
controls, the magnitude of differential expression was modest in terms of fold change in the case of most genes,
however differences in expression levels between groups were highly consistent across all subjects, which was
reflected by high levels of statistical significance in parametric statistical testing (Figure 2A). The combined
discriminatory power of the top ten genes was evident when their coordinate expression levels were plotted on
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a continuum for each individual subject; the overall pattern of expression was strikingly different between AIS
patients and controls, and it was clear that the overall pattern of expression was more diagnostically powerful
than the expression levels of any given gene on its own (Figure 2B).
In order to more intuitively explore the relationship between the pattern of gene expression observed
across the top ten genes and relevant clinical characteristics, we first used principle components analysis to
describe the expression levels of the top ten genes as single composite RNA expression variable. The
expression levels of the top ten genes were highly correlated, and a single principle component was able to
describe 70% of the collective variance in expression (Supplemental Table 1A). The result component scores
(composite RNA expression) were strongly correlated with the expression levels of each of the individual
candidate genes (Supplemental Table 1B), and visually appeared to summarize the gene expression pattern
well (Figure 2C).
We first used this composite RNA expression variable to examine the influence of potentially confounding
intergroup differences in clinical and demographic characteristics on the expression levels of the top ten genes.
Stroke, age, anticoagulant status, hypertension, antihypertensive status, dyslipidemia, history of myocardial
infarction, and history of atrial fibrillation were regressed against the composite RNA expression levels of the top
ten genes using multiple regression. We then performed variance decomposition via the LMG method to estimate
the relative contributions of each regressor to the total variance in composite RNA expression explained by the
resultant regression model.21 Stroke remained significantly associated with the composite RNA expression levels
of the top ten genes after accounting for all potentially confounding factors included in the model (Figure 3A),
and was responsible for a majority of the explained variance (77.9%, Figure 3B). In terms of potentially
confounding factors, both anti-hypertensive status and anticoagulant status were significantly associated with
the composite RNA expression levels of the top ten genes after accounting for all other regressors (Figure 3A),
however these associations only accounted for a small amount of the variance in composite RNA expression
explained by the model (6.5% and 4.5% respectively, Figure 3B). Results of this multiple regression analysis
were supported by the results of a more traditional logistic regression analysis in which the composite RNA
expression levels of the top ten genes were identified as the only significant predictor of stroke when considering
the same potentially confounding covariates (Supplemental Table 2). Taken as a whole, these findings suggest
that the pattern of differential expression observed across the top ten genes between groups is highly associated
with stroke independently of the assessed potential confounding factors. While these findings do suggest that
antihypertensive status and anticoagulant status may influence the expression levels of the top ten genes, the
effect of this influence on expression levels are likely minimal relative to the effect of stroke, and intergroup
differences in these factors were likely not significant drivers of the selection of these genes by GA/kNN.
We next used this used this composite RNA expression variable to examine the potential influence of
stroke severity and time to blood draw on the pattern of gene expression observed across the top ten genes.
The composite RNA expression levels of the top ten genes displayed a significant positive association with stroke
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severity as assessed by the NIHSS (Figure 4A), suggesting that the expression levels of the top ten genes are
likely directly responsive to stroke pathology. We observed a weak nonsignificant negative relationship between
the composite RNA expression levels of the top ten genes and the time from symptom onset to blood draw
(Figure 4B). However, this negative relationship was likely driven by the influence of stroke severity, given that
the composite expression levels of these genes were positively associated with stroke severity, and patients
undergoing more severe strokes generally presented to the emergency department earlier than patients
undergoing less severe strokes (Figure 4B). Collectively, these observations suggest that the stroke-induced
differential expression of the top ten genes may have additional utility for the stratification of stroke severity, and
is relatively temporally stable during the acute phase of care.
Validation Cohort:
We then tested the diagnostic ability of gene expression pattern identified in the discovery cohort in an
independent validation cohort enrolled via a second geographically and socioeconomically distinct clinical site
(see methods section). This validation cohort was comprised of an additional 39 AIS patients along with two
different control groups, one consisting of 30 neurologically asymptomatic controls, and the other consisting of
20 acute stroke mimics. Like in the discovery cohort, AIS patients were older than neurologically asymptomatic
controls, however, AIS patients and asymptomatic controls were better matched in terms of the prevalence of
co-morbidities and CVD risk factors (Table 2). AIS patients were also significantly older than stroke mimics,
however, extremely well matched in terms of all other clinical and demographic characteristics (Table 2).
Peripheral blood samples were once again obtained from patients at emergency department admission,
and the expression levels of the top ten genes identified by GA/KNN in the discovery cohort were measured via
qRT-PCR. The overall pattern of differential expression between AIS patients and asymptomatic controls
observed across the top 10 genes in the discovery cohort was also seen when comparing AIS patients and
asymptomatic controls in the validation cohort (Figure 5A). The strong ability of the top ten genes to differentiate
between stroke patients and asymptomatic controls in the discovery cohort using kNN was also recapitulated in
the validation cohort; the expression levels of the top ten genes used in combination were able to classify 95.6%
of subjects correctly with a sensitivity of 92.3% and a specificity of 100% (Figure 5B).
When comparing AIS patients to stroke mimics, the overall pattern of differential expression observed
across the top ten genes was identical to that observed when comparing AIS patients to asymptomatic controls,
however the magnitude of these expression differences was smaller in the case of several genes (Figure 5C).
Despite this reduction in the magnitude of differential expression, the expression levels of the top ten genes used
in combination were still able to accurately discriminate between AIS patients and stroke mimics, classifying
94.9% of subjects correctly with a sensitivity of 97.4% and a specificity of 90.0% (Figure 5D). However, it is
important to note that it was evident that all ten genes were required to achieve high levels of diagnostic accuracy
when comparing AIS patients to stroke mimics (Figure 5D), whereas similar levels of accuracy could be achieved
with as few as the top four markers when comparing AIS patients to neurologically asymptomatic controls in both
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the discovery cohort (Figure 1B) and the validation cohort (Figure 5B). Despite this, the collective validation
cohort results supported those of the discovery cohort, and provide further evidence that the top ten markers
selected by GA/kNN have high potential performance for identification of AIS.
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Discussion:
The primary objective of this study was to apply the GA/kNN approach to identify a pattern of gene
expression in peripheral blood which could potentially be optimized to identify AIS in the acute phase of care.
The ten transcriptional markers identified by GA/kNN in our analysis proved robust in their combined ability to
differentiate between AIS patients and controls in both the discovery cohort and the independent validation
cohort; not only did these markers display levels of diagnostic accuracy which exceed those reported in a majority
of previous stroke biomarker studies, they also demonstrated characteristics which suggest they have the
potential to be clinically useful. In addition to having diagnostic utility, some of the markers identified in this study
may represent viable therapeutic targets in the context of stroke immunopathology.
With regards to the countless number peripheral blood biomarker explorations which have been
performed to date, to our knowledge, only one prior investigation has reported similar levels of diagnostic
accuracy to those which we observed in this study in terms discriminating between stroke patients and clinically
relevant control populations. Dambinova et al.22 recently reported that plasma levels of brain-derived NR2
peptide, a degradation product of N-methyl-D-aspartate (NMDA) receptor cleavage, could be used to
differentiate between stroke patients and a combination of acute stroke mimics and neurologically asymptomatic
controls with 92% sensitivity and 96% specificity. However, a majority of blood samples in this prior study were
obtained between 24 and 72 hours post symptom onset, and it is currently unknown if NR2 peptide would exhibit
an equivalent level of diagnostic performance early in the acute phase of care. The ten marker panel identified
in our analysis was tested earlier in the progression of pathology, and thus exhibits an obvious advantage in that
it has the potential to provide actionable diagnostic information at an early enough time point to influence critical
triage decisions which impact outcome.
The ten marker panel identified in our analysis displayed several favorable characteristics which could
make it well suited for identification of ischemic stroke in the acute care setting. Most notably, the pattern of
differential expression we observed between AIS patients and controls appeared to be relatively temporally
stable. This is of clinical relevance from the standpoint that it is well established that acute stroke patients tend
to arrive to the emergency department in two waves, the first within four hours from symptom onset (typically
patients with more severe overt symptoms), and the second more than eight hours from symptom onset (typically
patients with milder symptoms).23 For this reason, a potential diagnostic for identification of acute stroke needs
to be diagnostically robust across a wide time window with regards to the progression of stroke pathology.
Another diagnostically beneficial characteristic we observed was that the stroke-associated pattern of expression
across these ten markers was positively correlated with the NIHSS. Thus, these markers may have utility in
stratifying injury severity, information which is commonly considered when making decisions regarding the
prescription of interventional treatment.4 These characteristics, along with the fact that we observed levels of
sensitivity and specificity which well exceed those achievable via the tools currently available to clinicians for the
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identification of stroke during acute triage, suggest that the ten marker panel identified in our analysis has
legitimate potential for future clinical implementation.
In addition to having diagnostic utility, some of the markers identified in this study may represent potential
therapeutic targets in the context of stroke immunopathology. Perhaps the most interesting of these markers
from this standpoint is CD163. It is well established that stroke induces a state of peripheral adaptive immune
suppression characterized by a limited capacity of lymphoid cells to respond to antigen.24,25 This suppressed
adaptive immune state leaves patients highly susceptible to post-stroke infection,26 which is the leading cause
of death in the post-acute phase of care.27 CD163 encodes for a protein known as cluster of differentiation 163
(CD163), a membrane-bound scavenger receptor for extracellular hemoglobin which is predominantly expressed
on immune populations of myeloid lineage.28,29 Mature CD163 is known to undergo ectodomain shedding to
generate a soluble truncated peptide (sCD163) which has been shown in multiple studies to directly interact with
lymphocytes and inhibit antigen mediated activation.30–32 Interestingly, we observed elevated RNA expression
levels of CD163 in the peripheral blood of AIS patients; it is possible that CD163 expression is increased in the
innate peripheral immune system in response to stroke-induced increases in circulating free hemoglobin,33
subsequently driving an increase in levels of circulating sCD163 which act to suppress lymphocyte activation. In
support of this hypothesis, unpublished preliminary data from our laboratory suggest that plasma levels of
sCD163 are elevated in AIS patients during the acute phase of care, and are positively correlated with RNA
expression levels of CD163 in whole blood. Ongoing work in our laboratory is aimed at characterizing the
relationship between peripheral blood sCD163 levels and stroke-induced adaptive immune dysfunction, as
CD163 may be therapeutically targetable as a means of rescuing adaptive immune responsiveness following
stroke.
In addition to CD163, the markers identified in this study included several other genes which may be
pathologically relevant within the context of the stroke-induced peripheral immune response. We observed
downregulated expression levels of MAL and GRAP in the peripheral blood of AIS patients; both genes encode
proteins which are critically involved in T-cell receptor activation and signal transduction.34,35 Furthermore, AIS
patients exhibited elevated expression levels of STK3, a gene encoding a seine threonine kinase involved in
pro-apoptotic signal transduction36,37 and suppression of lymphocyte proliferation.38 Taken as a whole, the
differential regulation we observed across these genes is consistent with suppressed adaptive immune state
induced in response to stroke, and may be mechanistically involved in blunting the responsiveness of the
adaptive immune system following ischemic brain injury. Conversely, two of the markers identified as being
upregulated in the peripheral blood of AIS patients in this study, KIF1B and ANTXR2, may be mechanistically
involved in the innate immune response to ischemic insult. It is well established that stroke induces robust
recruitment of myeloid-derived innate immune populations such as neutrophils and monocytes from the
peripheral blood into the brain parenchyma39,40; both genes encode proteins which have been shown to play a
role in cellular adhesion and migration,41–44 and thus may be mechanistically involved in this process.
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Collectively, the findings reported here are exciting, however, it is important to note that this study was
not without limitations. Perhaps most notably was the fact that AIS patients and neurologically asymptomatic
controls in our discovery cohort were not well matched with regards to several clinical and demographic
characteristics; thus, intergroup differences in these factors had the potential to confound the selection of stroke
specific genes in our GA/kNN analysis. To account for this possible limitation, we utilized a relatively high
termination cut-off for optimal solution selection; under these conditions, a confounding factor would have to be
almost ubiquitously present in one group, and nearly ubiquitously absent in the other, for it to influence the
selection of candidate genes. The results of our multiple regression analysis suggest that this strategy was
largely successful, however, they did infer that medication status may influence the expression of the candidate
genes. Despite this, the ten candidate genes were still able to demonstrate high levels of diagnostic accuracy
when discriminating between groups which were better matched in terms of these factors in the validation cohort.
Taken as a whole, the results of this preliminary study demonstrate that a highly accurate RNA-based
companion diagnostic for AIS is plausible using a relatively small number of markers, and also highlight the
potential power of machine learning approaches for biomarker discovery in the realm of CVD. The ten
transcriptional biomarkers identified in this study displayed levels of diagnostic performance which well exceed
those reported in a majority of previous stroke biomarker investigations, as well as several characteristics which
suggest they may have true clinical utility for identification of ischemic stroke during the acute phase of care.
Furthermore, future exploration of these markers may reveal novel mechanisms which underlie the peripheral
immune response to stroke, and lead to novel therapeutic targets in the context of stroke-induced
immunopathology. Due to the robust results of this preliminary analysis, the ten transcriptional biomarkers
identified in this study warrant further evaluation to determine their true clinical efficacy.

61

Methods:
Discovery cohort patients:
Acute ischemic stroke patients and neurologically asymptomatic controls were recruited at Suburban
Hospital, Bethesda, MD, which serves an upper-class metro area bordering Washington DC. AIS cases were of
mixed etiology, and diagnosis was confirmed by MRI according to the established criteria for diagnosis of acute
ischemic cerebrovascular syndrome (AICS).45 The median time from symptom onset to blood draw was 5.3
hours, as determined by the time the patient was last known to be free of AIS symptoms. In the case of patients
who received thrombolytic therapy, blood samples were collected prior to the administration of recombinant
tissue plasminogen activator (rtPA). Injury severity was determined according to NIHSS at the time of blood
draw. Control subjects were deemed neurologically normal by a trained neurologist at the time of enrolment.
Demographic information was collected from either the subject or significant other by a trained clinician. All
procedures were approved by the institutional review boards of the National Institute of Neurological
Disorders/National Institute on Aging at National Institutes of Health and Suburban Hospital. Written informed
consent was obtained from all subjects or their authorized representatives prior to any study procedures.
Blood collection and RNA extraction:
Peripheral whole blood samples were collected via PAXgene RNA tubes (Qiagen, Valencia, CA) and
stored at -80ºC until RNA extraction. Total RNA was extracted via PreAnalytiX PAXgene blood RNA kit (Qiagen)
and automated using the QIAcube system (Qiagen). Quantity and purity of isolated RNA was determined via
spectrophotometry (NanoDrop, Thermo Scientific, Waltham, MA). Quality of RNA was confirmed by chip capillary
electrophoresis (Agilent 2100 Bioanalyzer, Agilent Technologies, Santa Clara, CA).
RNA amplification and microarray:
RNA was amplified and biotinylated using the TotalPrep RNA amplification kit (Applied Biosystems,
Grand Island, NY). Samples were hybridized to HumanRef-8 expression bead chips (Illumina, San Diego, CA)
containing 25,000 unique probes and scanned using the Illumina BeadStation. Raw probe intensities were
background subtracted, quantile normalized, and then summarized at the gene level using Illumina
GenomeStudio. Sample labeling, hybridization, and scanning were performed per standard Illumina protocols.
Raw data are assessable through the National Center for Biotechnology Information Gene Expression Omnibus
via accession number GSE16561.
GA/kNN analysis:
Normalized microarray data were filtered based on absolute fold difference between stroke and control;
genes exhibiting a greater than 1.7 absolute fold difference in expression between AIS and control were retained
for analysis. Filtered gene expression data were z-transformed and GA/kNN analysis was performed using C
source code developed by Li et al.,20 compiled in Linux Mint. Two-thousand near-optimal solutions were collected
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per sample using five nearest neighbors, majority rule, a chromosome length of five, and a termination cutoff of
0.97. Leave one out cross validation was performed using the top 50 ranked genes. The top 50 genes were
tested against random gene combinations which were selected using the R sample() function (R 2.14, R Project
for Statistical Computing).
Validation cohort patients:
AIS patients, acute stroke mimics, and neurologically asymptomatic controls were recruited at Ruby
Memorial Hospital, Morgantown, WV, which serves an impoverished rural region of West Virginia which displays
some of the highest CVD rates in the nation.1 As with the discovery cohort, AIS cases were of mixed etiology,
and diagnosis was confirmed via neuroradiological imaging. Patients admitted to the emergency department as
suspected strokes based on the overt presentation of stroke-like symptoms, but receiving a negative diagnosis
for stroke upon imaging according to the established AICS diagnostic criteria45 were identified as acute stroke
mimics. Discharge diagnoses of stroke mimics included cases of seizures, complex migraines, and other
conditions which induce neurological symptoms such as hypertensive encephalopathy. The median time from
symptom onset to blood draw was 4.6 hours and all blood was sampled before the administration of rtPA.
Assessment of injury severity, screening of neurologically asymptomatic controls, and collection of demographic
information was performed in an identical manner. All procedures were approved by the institutional review
boards of West Virginia University and Ruby Memorial Hospital. Written informed consent was obtained from all
subjects or their authorized representatives prior to study procedures.
Quantitative reverse transcription PCR:
cDNA was generated from purified RNA using the Applied Biosystems high capacity reverse transcription
kit. For qPCR, target sequences were amplified from 10 ng of cDNA input using sequence specific primers
(Supplemental Table 3) and detected via SYBR green (PowerSYBR, Thermo-Fisher) on the RotorGeneQ
(Qiagen). Raw amplification plots were background corrected and CT values were generated via the
RotorGeneQ software package. All reactions were performed in triplicate. Transcripts of B2M, PPIB, and ACTB
were amplified as references and normalization was performed using the NORMAgene data-driven normalization
algorithm.46
Statistical analysis:
Parametric statistical analysis was performed using SPSS (IBM, Chicago, Ill) in combination with R 2.14
via the SPSS R integration plug-in. Chi-squared tests were used for comparison of dichotomous variables, while
student t-tests were used for comparison of continuous variables. Spearman’s rho was used to assess the
strength of correlational relationships. For multiple regression analysis, variance decomposition was performed
using the relaimpo R package.21 Penalized logistic regression was performed using the logistf R package.47 The
level of significance was established at 0.05 for all parametric statistical testing. In the cases of multiple
comparisons, p-values were adjusted using Holm’s Bonferonni method.48
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Figure legends:
Table 1. Discovery cohort clinical and demographic characteristics.
Table 2. Validation cohort clinical and demographic characteristics.
Figure 1. Top 50 genes selected by GA/kNN for identification of AIS.
(A) The top 50 peripheral blood transcripts ranked by GA/kNN based on their ability to discriminate between AIS
patients and neurologically asymptomatic controls in the discovery cohort. (B) Combined ability of the expression
levels of top 50 genes selected by GA/kNN to discriminate between AIS patients and neurologically
asymptomatic controls in the discovery cohort using kNN. (C) Ability of the expression levels of the top 50 genes
selected by GA/kNN to discriminate between neurologically asymptomatic controls and AIS patients via kNN
compared to the expression levels of genes selected at random. The accuracy of the top 10 genes selected by
GA/kNN was specifically tested against the accuracy of randomly selected genes using single sample two-way
t-test.
Figure 2. Differential expression of top ranked genes within the discovery cohort.
(A) Peripheral blood differential expression of the top ten genes selected by GA/kNN in discovery cohort
neurologically asymptomatic controls and AIS patients, with fold changes reported relative to control. Statistical
significance of intergroup differences in gene expression was determined via two-sample two-way t-test, and pvalues were corrected to account for multiple comparisons via Holm’s Bonferroni method. (B) Coordinate pattern
of peripheral blood expression across the top ten genes plotted for individual subjects in both experimental
groups. (C) Composite RNA expression levels of the top ten genes generated via principle components analysis.
Figure 3. Influence of potentially confounding clinical and demographic characteristics on the expression levels
of the top ten genes.
(A) Multiple regression model generated by regressing potentially confounding clinical and demographic
characteristics against the composite RNA expression levels of the top ten genes selected by GA/kNN in the
discovery cohort. (B) Graphical representation of the relative contribution of each regressor towards the total
variance in composite RNA expression explained by the model.
Figure 4. Influence of stroke severity and time to blood draw on the coordinate expression levels of the top
ranked genes in discovery cohort AIS patients.
(A) Relationship between stroke severity, as assessed by NIHSS, and composite RNA expression levels of the
top ten genes in discovery cohort AIS patients. (B) Relationship between time from symptom onset to blood draw
and composite RNA expression levels of the top 10 genes in discovery cohort AIS patients, with indication of
stroke severity. Strength of correlations were tested via Spearman’s rho.
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Figure 5. Differential expression and discriminatory ability of top ranked genes within the validation cohort.
(A) Peripheral blood differential expression of the top ten genes between validation cohort neurologically
asymptomatic controls and AIS patients. (B) Combined ability of the expression levels of the top ten genes to
discriminate between neurologically asymptomatic controls and AIS patients. (C) Peripheral blood differential
expression of the top ten genes between acute stroke mimics and AIS patients. (D) Combined ability of the
expression levels of the top ten genes to discriminate between acute stroke mimics and AIS patients. All gene
expression values are reported as fold change relative to control. Statistical significance of intergroup differences
in gene expression was determined via two-sample two-way t-test, and p-values were corrected to account for
multiple comparisons via Holm’s Bonferroni method.
Supplemental Figure 1. GA/kNN paradigm used for the selection of transcriptional biomarkers from highdimensional expression data.
(A) A first generation chromosome is generated via random selection from the total pool of gene expression
data. (B) The ability of the first generation chromosome to discriminate between groups is evaluated using kNN.
(A) If the chromosome passes evaluation, it is added to the pool of near-optimal solutions. If the chromosome
fails evaluation, it undergoes mutation and re-evaluation until a near-optimal solution is found. (C) This search
is repeated to generate a pool containing hundreds of thousands of near-optimal solutions. (D) Genes are then
ranked based on the number of times they appear in the near-optimal solution pool. (E) The combined
discriminatory ability of the top ranked genes is then tested in leave one out cross validation via kNN.
Supplemental Table 1. Use of principal components analysis for generation of a composite RNA expression
variable summarizing the coordinate expression levels of the top ten genes.
(A) Correlation matrix depicting the correlations between the expression levels of the top ten genes identified by
GA/kNN in the discovery cohort. Strength of correlations were tested via Spearman’s rho. (B) Principal
component loadings and coefficients used for generation of the composite RNA expression variable.
Supplemental Table 2. Influence of potentially confounding clinical and demographic characteristics on the
predictive power of the top ten genes identified by GA/kNN.
Firth’s penalized logistic regression was performed with stroke as the dependent variable and composite RNA
expression, age, anticoagulant status, hypertension, antihypertension medication status, dyslipidemia, history of
myocardial infarction, and history of atrial fibrillation as regressors. In the resultant model, composite RNA
expression remained a highly significant predictor of stroke after considering all other regressors. Furthermore,
none of the potentially confounding factors were significant predictors of stroke in the model.
Supplemental Table 3. Primers and thermocycling conditions used for qRT-PCR.
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Abstract:
The peripheral immune response to stroke plays a central role in pathology. Our group recently identified
a panel of ten genes whose whole blood expression levels can be used to identify acute ischemic stroke (AIS)
with high levels of accuracy. The purpose of this study was to determine the role of these transcriptional
biomarkers with regards to the stroke-induced peripheral immune response. We first aimed to identify where
these genes are expressed in the peripheral immune system by measuring their expression levels on six
leukocyte sub-populations isolated from the peripheral blood of healthy donors. All genes previously reported as
being upregulated in whole blood in response to stroke were predominantly expressed on populations of myeloid
origin, while all genes previously reported as being downregulated in stroke were predominantly expressed on
populations of lymphoid origin. We then examined the relationship between the expression levels of these genes
and the neutrophil-monocyte to lymphocyte ratio (NMLR) in whole blood obtained from 36 AIS patients at
emergency department admission. All genes previously reported as being upregulated in whole blood in
response to stroke were positively associated with NMLR, while all genes previously reported as being
upregulated in stroke were negatively associated with NMLR. We then demonstrated that these transcriptional
stroke biomarkers can be used as a surrogate measure of white blood cell differential that could potentially be
used to monitor stroke severity. Taken as a whole, these results suggest that these transcriptional stroke
biomarkers are differentially regulated in whole blood as markers of stroke-induced changes in white blood cell
count, and not changes at the level of transcription. Our findings not only provide insight into the mechanism by
which these transcripts are stroke biomarkers, but also into the results of other prior studies which have
performed whole blood expression profiling in stroke pathology.
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Introduction:
There are currently close to 800,000 strokes reported annually in the United States, and stroke is
responsible for 1 in every 19 mortalities.1 For those who survive, stroke constitutes a life altering event, with over
50% of patients requiring significant impatient rehabilitation or skilled nursing assistance upon discharge.1
Despite stroke’s prevalence and societal impact, therapeutic strategies aimed to improve stroke outcome remain
limited. It is becoming increasingly evident that the peripheral immune system plays a critical role in stroke
pathology, and may be therapeutically targetable as means of limiting secondary tissue damage and other
detrimental post-stroke complications.2–4
Stroke triggers an immediate systemic inflammatory response which results in a dramatic shift in the
phenotype of the peripheral immune system. The innate arm of the peripheral immune system undergoes rapid
expansion, as monocyte and neutrophil counts increase significantly in the hours following stroke onset. 5,6
Simultaneously, the adaptive arm of the immune system shifts into a state of suppression characterized by
lymphopenia and limited responsiveness.6–8 It has been hypothesized that this phenotypical shift may be an
evolutionarily conserved mechanism intended to provide an innate immune population to infiltrate the ischemic
region to aid in repair while simultaneously limiting the possibility of an adaptive autoimmune response directed
against central nervous system antigens.9 However, if this immune response becomes exaggerated or
prolonged, it constitutes a state of immune dysfunction that can severely impact stroke outcome.
If the innate immune system becomes excessively activated during the post-stroke immune response, it
can result in prolonged inflammation in and around the infarcted region, damage healthy tissues, and enhance
the injury.10,11 Furthermore, hyper-activation of innate immune system also increases the risk of developing poststroke BBB complications such as edema and hemorrhage,12 adverse events which are associated with poor
clinical prognosis.13–15 In terms of the adaptive immune system, if adaptive immune suppression becomes
prolonged, it leaves patients highly susceptible to post-stroke infection,5,6,16,17 which is the leading cause of death
in the post-acute phase of care.18 For these reasons, the presence of post-stroke peripheral immune dysfunction
is becoming increasingly linked to poor prognosis.
The status can of the peripheral immune system can be monitored via white blood cell differential in the
acute phase of care, and can be used predict stroke outcome. Elevated neutrophil to lymphocyte ratio (NLR) at
hospital admission has recently been linked to longer hospitalizations,19 and increased risk of mortality following
ischemic stroke.20–22 Similarly, heighted monocyte counts in the acute phase of care have been linked to
increased mortality risk after intracerebral hemorrhage.23 Despite the known associations between post-stroke
peripheral immune dysfunction and poor prognosis, the mechanisms which drive the peripheral immune changes
which occur in response to stroke remain unclear. Better understanding these mechanisms will undoubtedly lead
to future development of immune-based interventions aimed to improve stroke outcome.
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Our group recently identified a panel of ten genes whose expression levels are differentially regulated in
peripheral whole blood during stroke pathology which can be used to identify acute ischemic stroke (AIS) with
high levels of sensitivity and specificity.24 The expression levels of seven of these genes were demonstrated to
be upregulated in peripheral whole blood in response to ischemic stroke (ANTXR2, STK3, PDK4, CD163, CTSZ,
KIF1B, and PLXDC2), while the expression levels of the remaining 3 genes were demonstrated to be
downregulated (MAL, GRAP, and ID3). It is plausible that these genes play a mechanistic role in modulating the
peripheral immune changes which occur in response to stroke, however the role of these genes in post-stroke
immune pathology has yet to be explored. Thus, the purpose of this study was to gain a better understanding of
the potential role of these genes with regards to the stroke-induced peripheral immune response. We first aimed
to identify where these genes are expressed in the peripheral immune system, and then to determine the
relationship between the expression levels of these genes and stroke-induced peripheral immune dysfunction
and injury severity.
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Methods:
Experimental Design:
In order to determine where the previously identified stroke-associated genes are expressed in peripheral
blood, leukocyte sub-populations including neutrophils, monocytes, CD4+ T-lymphocytes, CD8+ T-lymphocytes,
B-lymphocytes, and NK-cells were isolated from peripheral blood samples obtained from three healthy donors.
qRT-PCR was then used measure expression levels of target genes in RNA extracted from the isolated subpopulations.
In order to determine the relationship between the peripheral blood expression levels of the previously
identified genes and stroke-induced peripheral immune dysfunction and injury severity, blood was sampled from
36 AIS patients and 15 acute stroke mimics at emergency department admission. Peripheral blood expression
levels of target genes were measured using qRT-PCR, peripheral immune status was determined via neutrophilmonocyte to lymphocyte ratio (NMLR), and injury severity was assessed via NIHSS and infarct volume. The
relationship between the expression levels of target genes, neutrophil-monocyte to lymphocyte ratio, NIHSS,
and infarct volume were assessed within the AIS group. Additionally, expression levels of target genes and
NMLR were compared between AIS patients and stroke mimics.
Participants:
Healthy donors, AIS patients, and stroke mimics were recruited from 2011 to 2015 at Ruby Memorial
Hospital, Morgantown, WV. For AIS patients, diagnosis was confirmed by MRI or CT. Patients admitted to the
emergency department with stroke-like systems but receiving a negative diagnosis for stroke upon imaging were
identified as stroke mimics. Samples were collected at ED admission, and always within 24 hours of symptom
onset, as determined by the time the patient was last known to be free of stroke symptoms. Injury severity was
determined according to the NIH stroke scale (NIHSS) at the time of blood draw. Demographic information was
collected from either the subject or significant other by a trained clinician. All procedures were approved by the
institutional review boards of West Virginia University and Ruby Memorial Hospital. Written informed consent
was obtained from all subjects or their authorized representatives prior to study procedures.
Blood collection:
Parallel peripheral intravenous whole blood samples were collected from subjects via PAXgene RNA
tubes (Qiagen, Valencia, CA) and K2EDTA Vacutainers (Becton Dickenson, Franklin Lakes, NJ). PAXgene RNA
tubes were frozen immediately and stored at -80ºC until RNA extraction, while K2EDTA tubes were stored at
room temperature until white blood cell differential (less than 30 minutes) or leukocyte isolation (performed
immediately).
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Isolation of leukocyte subpopulations:
Leukocytes were isolated from EDTA-treated blood via immuno-magnetic negative selection (EasySep
Direct, StemCell Technologies). Neutrophils, monocytes, CD4+ T-lymphocytes, CD8+ T-lymphocytes, Blymphocytes, and NK-cells were isolated from 4 mLs of blood per population according to the manufacture
recommended protocol. Isolated cells were rinsed once in PBS and lysed in Qiagen buffer RLT containing BME,
flash frozen in liquid nitrogen, and stored at -80 until RNA extraction.
RNA extraction and qRT-PCR:
Whole blood RNA was extracted from PAXgene tubes via the PreAnalytiX PAXgene blood RNA kit
(Qiagen) and automated using the QIAcube system (Qiagen). RNA was isolated from leukocyte lysates via the
RNeasy Micro kit (Qiagen). Quantity and purity of isolated RNA was determined via spectrophotometry
(NanoDrop, Thermo Scientific, Waltham, MA). cDNA was generated from purified RNA via Applied Biosystems
high capacity reverse transcription kit. For qPCR, target sequences were amplified from 10 ng of cDNA input
using previously published sequence specific primers (O’Connell et al. 2016, in press, npj Genomic Medicine)
and detected via SYBR green (PowerSYBR, Thermo-Fisher) on the RotorGeneQ (Qiagen). Raw amplification
plots were background corrected and CT values were generated via the RotorGeneQ software package. All
reactions were performed in triplicate. B2M, PPIB, and ACTB were amplified as reference transcripts and
normalization was performed using the NORMAgene data-driven normalization algorithm.
White blood cell differential and NMLR:
Complete blood count was obtained from EDTA-treated blood via optical flow cytometry and cellular
impedance using an automated clinical hematology analyzer (Cell-Dyn, Abbott Diagnostics, Santa Clara, CA).
NMLR was calculated as the geometric mean of absolute neutrophil and absolute monocyte count divided by
absolute lymphocyte count (NMLR = sqrt[neutrophil count*monocyte count] / lymphocyte count).
Neuroradiological imaging:
Neuroradiological imaging was performed using either MRI or CT within 24 hours of symptom onset. The
Brainlab iPlan software package was used to calculate infarct volume via manual tracing, and all infarct volume
calculations were verified by a neuroradiologist.
Statistics:
All statistics were performed using the GraphPad Prism statistical software package. Chi-squared test
was used for groupwise comparison of dichotomous variables. T-test or one-way ANOVA was used for
groupwise comparisons where appropriate. Spearman’s rho was used to test the strength of correlational
relationships. The null hypothesis was rejected when p<0.05.
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Results:
Transcriptional stroke biomarkers exhibit lineage specific expression in peripheral blood:
In order to get a better understanding regarding the potential role in of the previously identified strokeassociated genes in stroke-induced immune response, we first looked to identify where these stroke associated
genes are expressed in the peripheral immune system. Interestingly, almost every gene exhibited some degree
of lineage-specific expression. Each of the seven genes which have previously been shown to be up-regulated
in stroke were all predominantly expressed in cell populations of myeloid origin (Figure 1A, 1B, 1C, 1D, 1H, 1I,
1J). Conversely, all of genes which have been previously identified as being downregulated in the peripheral
blood following stroke were predominantly expressed in cells of lymphoid origin (Figure 1E, 1F, 1G). In some
cases, the difference in expression between myeloid and lymphoid populations was quite substantial, in excess
of hundred fold.
Expression levels of transcriptional stroke biomarkers are highly correlated with peripheral immune status:
We next explored the relationship between the expression levels of the previously identified strokeassociated genes and white blood cell differential in the peripheral blood of AIS patients at emergency
department admission. The whole blood expression levels of each of the seven genes which have previously
been shown to be up-regulated in stroke were to some degree positively associated with NMLR. Conversely, the
whole blood expression levels of all three genes which have previously been shown to be down-regulated in
stroke were negatively associated with NMLR.
Transcriptional stroke biomarkers can be used as a surrogate for white blood cell differential:
Because of the strong pattern of lineage-specific expression and the relationships we observed with
NMLR, we hypothesized that the changes in expression levels previously reported in whole blood are reflective
of stroke-induced changes in white blood cell count, and not by changes at the level of transcription. Thus, the
whole blood expression levels of these genes may serve as a surrogate for white blood cell differential. To
examine this possibility, we calculated a transcriptional-NMLR (tNMLR) by dividing the geometric mean of the
whole blood expression levels of the seven myeloid expressed genes by the whole blood expression levels of
the three lymphoid expressed genes (tNMLR = 7th root[ANTXR2*STK3*PDK4*CD163*CTSZ*KIF1B*PLXDC2] / 3rd
root[MAL*GRAP*ID3]).

We then examined the relationship tNMLR and white blood cell differential obtained NMLR

in the AIS group. Unsurprisingly, we observed a strong positive correlation between tNMLR and NMLR in the
peripheral blood of AIS patients at emergency department admission. These results support the idea that the
expression levels of these genes are a surrogate indicator of white blood cell differential.
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Transcriptional stroke biomarkers are associated with injury severity in a similar manner as white blood cell
differential:
Because NMLR has been shown to have diagnostic utility in stroke, we next aimed to determine whether
tNMLR could provide similar diagnostic information. Consistent with prior reports, NMLR was higher in AIS
patients than stroke mimics at emergency department admission. tNMLR was also elevated in stroke patients,
however to a greater degree of statistical significance. In terms of injury severity, both NMLR and tNMLR
exhibited positive associations with NIHSS in AIS patients at emergency department admission, however neither
relationship was statistically significant. NMLR and tNMLR were also both positively associated with infarct
volume, however only tNMLR exhibited a statistically significant relationship. Collectively, these results suggest
that a surrogate white blood cell differential derived from the expression levels of the previously identified
transcriptional stroke biomarkers can provide similar diagnostic information in the acute phase of care as NMLR.
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Discussion:
The primary objective of this study was to determine the potential role of ten transcriptional stroke
biomarkers previously identified by our group in stroke immunopathology. Our findings suggest that these ten
transcriptional biomarkers are most likely differentially regulated in whole blood as markers of stroke-induced
changes in white blood cell differential, and are likely not altered at the level of transcription in stroke pathology.
These results not only provide insight into our previous findings, but also into the findings of studies by other
groups which have tried to elucidate mechanisms of stroke immunopathology using expression profiling data
generated from whole blood. Furthermore, our results also reaffirm the potential diagnostic usefulness of white
blood cell differential in stroke, and suggest that transcriptional biomarkers could be used as a surrogate measure
in cases where cytometry is not available, such as in pre-clinical settings.
It is well established that neutrophil and monocyte counts increases early in stroke pathology, 5,6 while
lymphocyte counts drop.6,7 All seven genes which we previously identified as being upregulated in whole blood
in response to stroke were predominantly expressed in myeloid cell populations and positively associated with
NMLR. All three genes which we previously identified as being down regulated in AIS were predominantly
expressed in lymphoid cell populations and negatively associated with NMLR (summarized in Table 2). Taken
as a whole, this suggests that these genes are likely not differentially regulated at the level of transcription in
response to stroke, and likely exhibit altered expression in whole blood simply as markers of changes in white
blood cell differential. While this does not diminish the diagnostic potential of these genes as biomarkers, it
suggests they may not play a substantial mechanistic role in driving stroke immune pathology.
Two previous studies have used microarray for expression profiling of whole blood in an attempt identify
mechanisms which drive stroke-induced immunopathology.25,26 Our findings suggest that it is plausible that many
of the genes identified as being differentially regulated in these studies exhibit altered expression in stroke as
markers of changes in white blood cell differential as well. This would suggest that the biological mechanisms
implied by these studies may in some ways be flawed. To assess this possibility, we measured the leukocyte
sub-population expression levels of three genes identified these studies which have been suggested to play a
mechanistic role in driving post stroke immune suppression. Expression levels of ARG1 and NPL were
demonstrated to be upregulated in whole blood in in response to stroke in both studies, expectedly, we observed
hundreds to thousands fold higher expression levels of these genes on cells of myeloid origin than on cells of
lymphoid origin (Supplemental Figure 1A, 1B). These studies identified expression levels of CCR7 as being
downregulated in whole blood in response to stroke; expectedly, we observed hundreds fold higher expression
levels on cells of lymphoid origin than on cells of myeloid origin (Supplemental Figure 1C). While not definitively,
these observations provide reason to believe that at least some of the genes suggested by these whole blood
expression profiling studies as being mechanistic drivers of stroke immunopathology exhibit altered expression
in whole blood simply as markers of changes in WBC differential, and may not play as mechanistic of a role as
previously suggested. Genes which play a central mechanistic role in stroke immunopathology are likely ones
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which are differentially regulated at the level of transcription. Our collective observations suggest that that
changes in white blood cell differential which occur in response to stroke makes reliably identifying such genes
in whole blood unrealistic. Future studies which aim to use expression profiling of the peripheral immune system
should take care to avoid this confound by measuring stroke induced changes in isolated leukocyte subpopulations or on single cells.
Our finding supports prior work which suggest white blood cell differential could be diagnostically useful
in the acute phase of care.19–22,27–29 Prior studies have focused on the use of neutrophil to lymphocyte ratio (NLR)
as a diagnostic marker in stroke, while to our knowledge, this study was the first to examine NMLR. Several of
these studies have demonstrated that NLR is elevated in AIS patients early in pathology28,29 and is associated
with injury severity.19,20,27 Similarly, in this study, we observed that NMLR was significantly higher in AIS patients
at emergency department admission as opposed to stroke mimics, and is to some degree positively associated
with injury severity. Interestingly, we observed more distinct differences in NMLR between AIS patients and
stroke mimics compared to NLR as well as stronger associations between injury severity and NMLR than NLR
(data not shown). These observations suggest that NMLR may be more diagnostically robust than NLR, however
future study in a larger sample size would have to be used to definitely draw such a conclusion. Furthermore,
our results suggest that the ten transcriptional stroke biomarkers identified by our previous work could be used
as a surrogate measure for NMLR.
Having a rapidly assessable surrogate measure of white blood cell differential could be diagnostically
useful in the prehospital setting. Assessment of white blood cell differential by cytometry is cumbersome and
expensive, limiting its accessibility in the field. However, recent advances in nucleic acid detection suggest that
cost-effective rapid quantification of nucleic acids via portable devices will soon be possible. 30 Thus, the
transcriptional biomarkers explored in this study may be able to serve as a surrogate measure of WBC differential
that is field assessable to first responders. Such an assessment could be valuable in making triage decisions
with regards to potential strokes. Because it has been established that alterations in white blood cell differential
are associated with injury severity19,20,27 and predictive of mortality,20–22 a field assessment which could provide
similar diagnostic information could be used to identify high risk patients early and allow for transport to more
stroke-ready facilities. Additionally, such a diagnostic assessment may be of value in resource-poor world
regions where the prevalence of stroke is dramatically increasing,31 however access to modern medical
technologies such as cytometry or neuroradiological imaging are limited.
We have already established that the transcriptional biomarkers explored in this study can be used to
identify AIS with high levels of sensitivity and specificity; our results suggest that their expression levels are
altered in peripheral whole blood as markers of stroke-induced changes in white blood cell count. These findings
not only provide insight into the mechanism by which these transcripts are stroke biomarkers, but also into the
results of other prior studies which have performed whole blood expression profiling in stroke pathology.
Additionally, our results also reaffirm the potential diagnostic usefulness of white blood cell differential in stroke,
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and suggest that transcriptional biomarkers have the potential to be used as a surrogate measure in the preclinical setting.
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Figure Legends:
Table 1. Clinical and demographic characteristics
Table 2. Summary
Figure 1. Expression levels of transcriptional stroke biomarkers on isolated leukocyte sub-populations.
Expression levels of (A) ANTXR2, (B) STK3, (C) PDK4, (D) CD163, (E) MAL, (F) GRAP, (G) ID3, (H) CTSZ, (I)
KIF1B, and (J) PLXDC2 in peripheral whole blood and isolated leukocyte populations obtained from one male
and two female healthy donors. Expression levels are presented as fold change relative to the population of
lowest expression.
Figure 2. Relationships between whole blood expression levels of transcriptional stroke biomarkers and
peripheral immune status in AIS patients.
Relationship between peripheral whole blood expression levels of (A) ANTXR2, (B) STK3, (C) PDK4, (D) CD163,
(E) MAL, (F) GRAP, (G) ID3, (H) CTSZ, (I) KIF1B, and (J) PLXDC2 and NMLR in AIS patients at emergency
department admission.
Figure 3. Relationship between NMLR and tNMLR
Relationship between NMLR and tNMLR in peripheral blood of AIS patients at emergency department admission.
Figure 4. Relationship between tNMLR and measures of injury severity.
(A) NMLR and (B) tNMLR in AIS patients and stroke mimics at emergency department admission. Relationships
between both (C) NMLR and (D) tNMLR and NIHSS in AIS patients at emergency department admission.
Relationships between both (E) NMLR and (F) tNMLR and infarct volume in AIS patients at emergency
department admission. Infarct volume categories comprised of three groups of twelve patients each.
Supplemental Figure 1. Cell population-specific expression levels of genes highly cited as being potential
drivers of stroke immunopathology based on the finding of prior stroke microarray investigations performed in
whole blood.
Expression levels of (A) NPL, (B) ARG1, and (C) CCR7 in peripheral whole blood and on isolated leukocyte
populations obtained from one male and two female healthy donors. Expression levels are presented as fold
change relative to the population of lowest expression, and were statistically compared via one-way ANOVA.
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Abstract:
The peripheral adaptive immune system responds to stroke by shifting into a state of suppression. While
it is becoming increasingly evident that the duration and magnitude of this response significantly influences
patient outcome, its underlying mechanisms are not yet fully understood. CD163 is a myeloid-expressed
scavenger receptor which can be shed from the plasma membrane via the metalloprotease ADAM17 to generate
a soluble peptide which is known to directly interact with lymphocytes and exert inhibitory effects. Based on prior
observations of elevated transcriptional levels of CD163 in the peripheral blood of ischemic stroke patients, we
hypothesized that CD163 may be a mediator of stroke-induced adaptive immune suppression. To address this
hypothesis, we first assessed cellular ADAM17 activity and soluble CD163 levels in the peripheral blood of a
modestly-sized cohort of ischemic stroke patients (n=39), neurologically asymptomatic controls (n=20), and
acute stroke mimics (n=20). ADAM17 activity and soluble CD163 levels were elevated in ischemic stroke patients
relative to control groups, and negatively associated with post-stroke lymphocyte counts. Subsequent in vitro
experiments suggested that this stroke-induced elevation in circulating soluble CD163 likely originates from
monocytes, as serum from ischemic stroke patients stimulated ADAM17-dependant CD163 shedding in primary
monocyte cultures generated from the peripheral blood of healthy individuals. Additional in vitro experiments
further suggested that post-stroke elevations in circulating soluble CD163 have the capacity to elicit direct
suppressive effects on the adaptive immune system, as serum from ischemic stroke patients inhibited the
proliferation of healthy donor-derived lymphocytes, an effect which was partially ameliorated following serum
CD163 depletion. Collectively, these observations novelly suggest that CD163 plays a mechanistic role in
modulation of peripheral immunity following ischemic stroke, as a factor directly linking innate immune system
activation and adaptive immune suppression.
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Introduction:
Stroke triggers a systemic inflammatory response which results in a dramatic shift in the phenotype of
the peripheral immune system. The innate arm of the peripheral immune system undergoes rapid activation, a
phenomenon which results in significant elevations in circulating neutrophil and monocyte counts in the hours
following onset.1,2 Conversely, the adaptive arm of the peripheral immune system shifts into a state of
suppression, often characterized by a prolonged period of lymphopenia and limited antigen responsiveness.2–4
While the pathophysiological role of the innate immune response to stroke has been long appreciated, a growing
body of evidence suggests that the adaptive immune response to stroke also critically influences patient
outcome.
It is likely that the state of adaptive immune suppression which develops in response to stroke largely
serves to limit the possibility of an autoimmune response as the blood brain barrier becomes disrupted and the
peripheral immune system becomes exposed to unfamiliar central nervous system (CNS) antigens.5 Expectedly,
heightened adaptive immune activity immediately following stoke has been shown to prolong the inflammatory
state and promote secondary tissue damage, factors which can ultimately contribute to poor prognosis. 6 While
the state of adaptive immune suppression is acutely protective, if prolonged, it can constitute a significant
detriment to recovery.7–11 Patients which display prolonged adaptive immune suppression following stroke
become highly susceptible to post-stroke infection,12–15 which is one of the leading causes of death in the postacute phase of care.8 Despite the fact that is becoming increasingly evident that this delicate balancing act
between maintenance of self-tolerance and pathogen susceptibility plays a significant role in recovery, the
mechanisms which drive the peripheral adaptive immune response to stroke are not yet fully understood.
CD163 is a membrane-bound scavenger receptor for extracellular hemoglobin which is believed to be
expressed exclusively within the innate immune system,16 where it is predominantly found on monocytes and
macrophages,17 and to a lesser extent on neutrophils.18 Various stimuli can trigger CD163 ectodomain shedding
via cleavage by the metalloprotease ADAM metallopeptidase domain 17 (ADAM17),19,20 resulting in generation
of a soluble truncated peptide (sCD163) which has been shown in multiple studies to directly interact with
lymphocytes and inhibit antigen-induced proliferation.21–23 Interestingly, a genome-wide transcriptomic screen
performed by our group recently identified CD163 as being robustly up-regulated in the peripheral blood of
ischemic stroke patients within hours of system onset (O’Connell et al. 2016, in-press, npj Genomic Medicine).
Furthermore, other groups have reported heightened ADAM17 activity in animal models of ischemic brain
injury,24–26 as well as stroke-induced increases in peripherally circulating levels of various ADAM17 substrates
such as tumor necrosis factor alpha (TNFα) in human subjects.27,28 Therefore, it is possible that stroke induces
a rise in peripherally circulating levels of sCD163 via coordinate increases in CD163 expression and ADAM17
activity; such a rise in sCD163 levels could subsequently contribute to suppression of the adaptive immune
system via the inhibitory effects of sCD163 on lymphocyte activity. Thus, the primary objective of this study was
to investigate sCD163 as a potential modulator of post-stroke adaptive immune suppression.
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Results:
In order to determine whether stroke drives an increase in peripheral sCD163 production in vivo, we first
recruited 39 acute ischemic stroke patients (AIS) along with two control groups, the first consisting of 20
neurologically asymptomatic subjects, and the second consisting of 20 acute stroke mimics (Table 1). Peripheral
venous blood was sampled within 24 hours of symptom onset, and expression levels of ADAM17 and CD163
were assessed in terms of RNA and protein using a combination of qRT-PCR, enzyme activity assay, and ELISA.
Consistent with our previous reports, transcriptional levels of both ADAM17 and sCD163 were elevated
in the whole blood of AIS patients relative to that of control groups (Figure 1A, 1B). Protein assays supported
these observations, as AIS patients displayed heightened cellular ADAM17 activity in total hemocyte fractions
generated from peripheral blood (Figure 1C), as well as elevated plasma levels of sCD163 (Figure 1D).
Furthermore, both cellular ADAM17 activity and plasma sCD163 levels displayed positive associations with
stroke severity in terms of NIHSS (Figure 1E, 1F) and infarct volume (Supplemental Figure 1A, 1B); while our
relatively small sample size and the variability inherent to such measures of injury status kept these associations
from reaching statistical significance, these relationships tentatively inferred that both factors are directly
responsive to stroke pathology. Taken as a whole, these observations provided associative evidence supporting
our hypothesis that stroke induces a peripheral rise in sCD163 levels via increased ADAM17 activity.
To explore whether the elevations in sCD163 levels which we observed in AIS play a role in modulation
of the stroke-induced peripheral immune response, we next assessed the relationship between circulating
sCD163 levels and white blood cell counts within the AIS group. Plasma sCD163 levels were significantly
negatively associated with post-stroke absolute lymphocyte counts (Figure 2A), as well as significantly positively
associated with both absolute monocyte counts (Figure 2B) and absolute neutrophil counts (Figure 2C).
Collectively, these results provided in vivo associative evidence which supported our hypothesis that strokeinduced increases in myeloid-derived circulating sCD163 may contribute to post-stroke suppression of the
adaptive immune system.
Next, we wanted to determine the direct effects of the post-stroke peripheral inflammatory milleu on
ADAM17-mediated sCD163 shedding by peripheral blood innate immune cell populations. To do this, primary
neutrophil and monocyte cultures generated from the peripheral blood of twelve healthy donors (Supplemental
Table 1) were treated with pooled serum samples derived from a subset of ten AIS patients, ten neurologically
asymptomatic controls, and ten acute stroke mimics which were relatively well matched in terms of clinical and
demographic characteristics (Table 2). Serum incubation was performed in both the presence and absence of
the ADAM17 inhibitors TAPI-0 and Marimastat, and cellular ADAM17 activity and sCD14 production were
assessed following treatment.
Neutrophil cultures across all treatment conditions appeared largely phenotypically identical when
visually inspected following treatment (Figure 3A). ADAM17 activity did appear to be elevated in neutrophil
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cultures treated with serum obtained from AIS patients relative to those treated with serum obtained from both
neurologically asymptomatic controls and acute stroke mimics, however this increase was not statistically
significant (Figure 3B). Overall, neutrophil cultures appeared to generate relatively little sCD163, although a
limited number of cultures treated with AIS serum did appear to exhibit increased sCD163 production in response
to treatment. This effect was not widespread however, and no statistically significant differences were observed
in sCD163 production between cultures treated with AIS serum and those treated with serum from control groups
(Figure 3C). A second independent experiment using pooled serum samples derived from a separate sub-set
of subjects (Supplemental Table 2) yielded similar results (Supplemental Figure 2).
Counter to what was observed in terms of neutrophil cultures, there were striking visual differences
between monocyte cultures treated with serum derived from AIS patients and those treated with serum derived
from control groups. Cultures treated with control serum generally displayed a mix of adherent and semiadherent cells, however several cultures incubated with AIS serum contained large patches of cells which
appeared highly adherent with prominent cytoplasmic vacuoles characteristic of a shift towards a macrophage
phenotype (Figure 4A). ADAM17 activity was significantly elevated in monocytes treated with AIS serum relative
to those treated with serum from both control groups (Figure 4B). Furthermore, supernatants recovered from
cultures treated with AIS serum contained significantly higher concentrations of monocyte-derived sCD163 than
those recovered from cultures treated with serum from either control group, and this effect was largely ablated
by inhibition of ADAM17 (Figure 4C). Once again, similar results were observed in a second independent
experiment (Supplemental Figure 3) using pooled serum samples derived from a separate sub-set of subjects
(Supplemental Table 2). Collectively, these observations demonstrate that soluble factors present in peripheral
circulation following ischemic stroke have the capacity to trigger ADAM17-dependant sCD163 shedding from
peripheral blood monocytes, however likely not from neutrophils.
Lastly, we wanted to determine the direct effect of post-stroke-elevations in circulating sCD163 levels on
the capacity of the peripheral blood to support lymphocyte proliferation. To do this, PHA-stimulated proliferation
of healthy-donor derived lymphocytes was assessed via BrdU incorporation in the presence of pooled serum
obtained from control groups, pooled serum from AIS patients, and pooled serum obtained from AIS patients
which had been depleted of sCD163 by immunoprecipitation (Supplemental Figure 4). Consistent with prior
reports,29 visual observations suggested decreased proliferative activity in lymphocyte cultures treated with
unmanipulated AIS serum relative to those treated with serum from control groups, as they appeared to contain
smaller and more diffuse clusters of blasting lymphocytes (Figure 5A). However, visual indications suggested
that the inhibitory effect of AIS serum was at least moderately counteracted by the depletion of sCD163 (Figure
5A). In agreement with these visual observations, we observed significantly lower levels of BrDU incporperation
in lymphocytes stimulated in the presence of AIS serum relative to those which were stimulated in the presence
of serum derived from control groups, an effect which was partially ablated as a result of sCD163 depletion
(Figure 5B). A second independent experiment using pooled serum samples derived from a separate sub-set of
subjects (Supplemental Table 2) yielded similar results (Supplemental Figure 5). Taken together, these results
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novelly suggest that post-stroke elevations in circulating levels of sCD163 can have direct inhibitory effects on
the proliferative capacity of lymphocytes.
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Discussion:
The primary objective of this work was to determine the role of CD163 within the context of stroke
immunopathology. We hypothesized that coordinate elevations in CD163 expression and ADAM17 activity
induced by stroke could drive increases in circulating levels of sCD163, which could ultimately contribute to
suppression of the peripheral adaptive immune system via the known inhibitory effects of sCD163 on lymphocyte
activity. Our collective findings supported our hypothesis, and suggest that sCD163 plays a unique role as a
factor which synergistically links stroke-induced activation of the innate immune system and suppression of the
adaptive immune system. Such a mechanism illustrates a departure from the often compartmentalized view of
stroke immunopathology, and highlights the necessity to approach the peripheral immune system from a global
perspective in future work, especially with regards to immunotherapeutic design.
Observations of elevated levels of sCD163 in the peripheral blood of AIS patients, along with the fact that
these elevations were negatively associated with lymphocyte counts, provided in vivo associative evidence
supporting our hypothesis that CD163 plays a role in modulation of the adaptive immune system following stroke.
Furthermore, our in vitro observations suggested that this stroke-driven increase in circulating sCD163 most
likely originates from peripheral blood monocytes, as serum from AIS patients stimulated ADAM17-dependant
production shedding in monocyte cultures generated from the peripheral blood of healthy individuals. Our in vitro
observations further suggested that stroke-induced elevations in circulating sCD163 have the capacity to elicit
direct suppressive effects on the adaptive immune system, as depletion of sCD163 from AIS patient-derived
serum was able to partially rescue its capacity to support lymphocyte proliferation. Collectively, our findings infer
a mechanism in which peripherally circulating factors induced by stroke trigger ADAM17-dependant CD163
shedding by monocytes, driving an increase in sCD163 levels which act to suppress peripheral lymphocyte
activity, likely as means of mitigating the risk of an adaptive immune response directed against CNS antigens
(Supplemental Figure 6).
To our knowledge, our results are the first to demonstrate a direct role for the innate immune system in
mediating stroke-induced suppression of the peripheral adaptive immune system. While our results highlighted
sCD163 as a means of such cross-communication, it is likely other innate-derived factors function to mediate
the adaptive immune response to stroke via similar mechanisms. This notion is accentuated by the fact that
complete ablation of sCD163 from stroke-derived serum was not adequate to fully rescue its capacity to support
lymphocyte proliferation, inferring that there are a multitude of other soluble factors present in post-stroke
peripheral circulation which have similar inhibitory effects. While the origins of these factors are inevitably
diverse, it is likely that some arise via a similar mechanism as sCD163, as biological mechanisms are often
redundant.30 Interesting from this regard is cluster of differentiation 14 (CD14), a membrane-bound pattern
recognition receptor which is largely exclusive to the innate immune system.31,32 Much like CD163, CD14 can be
shed via an MMP-dependent mechanism to generate a soluble protein (sCD14) which has been shown to directly
interact with lymphocytes and exert suppressive effects.33,34 Preliminary results from our laboratory suggest that
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circulating levels of sCD14 are also elevated in response to stroke, and further exploration may reveal that sCD14
plays similar role as sCD163 in modulation of the peripheral adaptive immune response.
While this study identified a clear role for sCD163 in stroke immunopathology in terms of its end-action,
our experiments did not look to identify the soluble factors present in peripheral circulation following stroke which
are responsible for triggering the shedding of CD163 from monocytes. It is plausible to believe that this
phenomenon is likely driven by a synergistic combination of stroke-induced damage associated molecules
(DAMs), cytokines, and hormones, as members of the aforementioned families of factors are known to stimulate
CD163 shedding. Notable from this standpoint is extracellular hemoglobin, a DAM which has been previously
demonstrated as being acutely elevated in peripheral circulation following stroke as a result of intravascular and
extravascular hemolysis.35 Free hemoglobin has been characterized as a potent inducer of CD163 shedding, 36
and thus, may help drive production of sCD163 in response to stroke. Along similar lines, levels of interleukin-6,
cortisol, and reactive oxygen species, are all known to be elevated acutely in stroke pathology, 27,37,38 and all have
been shown to promote sCD163 production.39,40 Further exploration into these and other potential molecular
signals which may trigger sCD163 generation within the context of stroke could not only provide a more complete
picture of the mechanisms identified in this study, but a better understanding of post-stroke adaptive immune
suppression as a whole, as the factors which drive post-stroke sCD163 production likely exert suppressive
effects on the peripheral immune system via multiple parallel mechanisms.
While our findings are exciting, it is important to note that potentially confounding the interpretation of our
results is the fact that elevations in sCD163 have been previously reported in atherosclerosis as a result of
excessive intravascular macrophage activity within atherosclerotic plaques.41 As atherosclerosis is closely linked
with stroke as one of its primary pathogenic drivers, 42 it leaves open the possibility that our results were
atherosclerosis driven, and not by the acute event of stroke itself. However, we find this scenario unlikely, as
subjects in our control groups were well matched with AIS patients in terms of the prevalence of cardiovascular
disease risk factors associated with atherosclerosis. Supporting our notion that the elevations in sCD163 which
we observed in AIS were a direct result of the stroke-induced neurological insult is the fact that it has recently
been reported that levels of macrophage-derived sCD163 are elevated in the cerebrospinal fluid of pediatric
traumatic brain injury patients,43 providing concurrent evidence that cerebral trauma has the capacity to directly
trigger increased sCD163 production. Furthermore, our findings, taken with theirs, suggest the possibility that
stroke-induced elevations in sCD163 may not only modulate adaptive immune activity in the periphery, but could
also serve a similar function within the lesion in terms of adaptive cellular infiltrates.
From a broader perspective, our findings are intriguing as they demonstrate a departure from the
compartmentalized view of stroke immunopathology. While there are some exceptions, research regarding
stroke immunopathology has long and too often treated the adaptive and innate immune responses as
independent entities, however our results and those of select others suggest that these responses are likely
synergistically linked via direct mechanisms. This realization is of utmost importance with regards to the current
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push towards the development of novel stroke therapeutics which target the peripheral immune system.
Currently, experimental immune therapies are being developed which largely aim to improve stroke outcome via
one of two often discrete avenues: either by inhibiting the acute innate immune response to stroke as means of
limiting excessive tissue damage and mitigating the risk of negative secondary cerebrovascular events such as
edema and hemorrhagic transformation,44–46 or by post-acutely stimulating the peripheral adaptive immune
system as a means of limiting the risk of complications induced by post-stroke infection.47–50 However,
immunotherapeutics proposed along this line of thinking often fail to account the possible interplay between the
adaptive and innate immune systems, and the potential repercussions that could stem from modulating one
response without consideration for the other.
A perfect example in this regard is the fact that ADAM17 inhibitors are often cited as a potential stroke
therapeutic under the premise that they could ultimately limit excessive innate-driven inflammation and its
associated complications via a reduction in TNFα production.51–54 However, our results clearly demonstrate that
inhibition of ADAM17 within the innate immune system could directly interfere with mechanisms which act to
suppress the adaptive immune system, an unintended effect which could put patients at elevated risk for the
development of long-term autoimmune complications associated with loss of CNS self-tolerance. Such an
example highlights the necessity for a global view regarding the peripheral immune system in terms of the
development of novel stroke immunotherapeutics. Unfortunately, therapeutic design from such a perspective is
currently unrealistic, as the mechanisms which drive the stroke-induced peripheral immune response, particularly
that of the adaptive immune system, are still largely unknown. This current gap in knowledge may underlie the
reality that stroke immunotherapeutics have thus-far been largely unsuccessful.55 Further future work which aims
to characterize the peripheral immune response to stroke and its underlying mechanisms from a panoptic
systems biology approach, preferably within human-centric models, would likely generate the foundational basis
for the development of stroke immunotherapeutics with higher chances for clinical success.
Collectively, our results demonstrate a novel role for CD163 as factor which mechanistically couples
stroke induced-activation of the peripheral innate immune system and suppression of the peripheral adaptive
immune system. Our results provide a unique example which suggests that the innate immune system employs
protective mechanisms aimed at mitigating the risk of post-stroke autoimmune complications driven by adaptive
immune system overactivation. Further work which looks to characterize similar pathways of crosscommunication between the innate and adaptive immune systems within the context of stroke would likely
provide a better understanding of stroke pathology as a whole, and allow for more informed development of
stroke-targeted immunotherapeutics.
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Methods:
Patients:
AIS patients, acute stroke mimics, and neurologically asymptomatic controls were recruited at Ruby
Memorial Hospital, Morgantown, WV. AIS cases were of mixed etiology, and diagnosis was confirmed by
neuroradiological imaging according to the established criteria for diagnosis of acute ischemic cerebrovascular
syndrome.56 Patients admitted to the emergency department as suspected strokes based on the overt
presentation of stroke-like symptoms, but receiving a negative diagnosis for stroke upon imaging were identified
as acute stroke mimics.56 Discharge diagnoses of stroke mimics included cases of seizures, complex migraines,
and other conditions which induce neurological symptoms such as hypertensive encephalopathy. Blood was
sampled within 24 hours of onset, as determined by the time the patient was last known to be free of AIS
symptoms. In the case of patients who received thrombolytic therapy, blood samples were collected prior to the
administration of recombinant tissue plasminogen activator (rtPA). Injury severity was determined according to
NIHSS at the time of blood draw. Control subjects were deemed neurologically normal by a trained neurologist
at the time of enrolment. Demographic information was collected from either the subject or significant other by a
trained clinician. All procedures were approved by the institutional review boards of West Virginia University and
Ruby Memorial Hospital. Written informed consent was obtained from all subjects or their authorized
representatives prior to study procedures.
Neuroradiological imaging:
Neuroradiological imaging was performed using either MRI or CT within 24 hours of symptom onset. CT
imaging was performed on either a Toshiba Aquilion 64 or Toshiba Aquilion 320 scanner (5 mm slices acquired
at 120 KVp, 250 mA). MRI imaging was performed using either a Siemens Aera or Siemens Verio scanner (5
mm slices, 5 mm inter-slice gap, acquired via diffusion-weighted echoplanar imaging with a B-factor of 1000
s/mm2). The BrainLAB iPlan Neuroradiology software package (BrainLAB, Westchester, Ill) was used to calculate
infarct volume via manual tracing as previously described,57 and all infarct volume calculations were verified by
an experienced neurologist.
Blood collection:
Parallel peripheral intravenous whole blood samples were collected from subjects via PAXgene RNA
tubes (Qiagen, Valencia, CA), K2EDTA Vacutainers (Becton Dickenson, Franklin Lakes, NJ), and serum
separator tubes (Becton Dickenson). PAXgene RNA tubes were frozen immediately and stored at -80ºC until
RNA extraction. K2EDTA tubes were stored at room temperature until white blood cell differential (less than 30
minutes), plasma isolation (less than 30 minutes), or leukocyte isolation (performed immediately). Serum
separator tubes were stored at room temperature until serum isolation (less than 30 minutes).
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Isolation of serum and plasma:
For plasma isolation, EDTA-treated blood was spun at 2,000*g for 10 minutes to sediment hemocytes.
Plasma was collected for ELISA, and the total hemocyte fraction was retained for subsequent protein extraction.
Plasma was additionally spun at 10,000*g for 10 minutes to remove any residual blood cells or debris. For serum
isolation, serum separator tubes were incubated at room temperature for a minimum of 15 minutes to allow for
clot formation, and subsequently spun at 2,000*g for 10 minutes to sediment the resulting thrombus. Resultant
samples were stored at -80ºC until analysis.
RNA extraction:
Whole blood RNA was extracted from PAXgene tubes via the PreAnalytiX PAXgene blood RNA kit
(Qiagen) and automated using the QIAcube system (Qiagen). RNA was isolated from leukocyte lysates via the
RNeasy Micro kit (Qiagen). Quantity and purity of isolated RNA was determined via spectrophotometry
(NanoDrop, Thermo Scientific, Waltham, MA). Quality of RNA was confirmed by chip capillary electrophoresis
(Agilent 2100 Bioanalyzer, Agilent Technologies, Santa Clara, CA).
Quantitative reverse transcription PCR:
cDNA was generated from purified RNA using the Applied Biosystems high capacity reverse transcription
kit. For qPCR, target sequences were amplified from 10 ng of cDNA input using sequence specific primers
(Supplemental Table 3) and detected via SYBR green (PowerSYBR, Thermo-Fisher) on the RotorGeneQ
(Qiagen). Raw amplification plots were background corrected and CT values were generated via the
RotorGeneQ software package. All reactions were performed in triplicate. Transcripts of B2M, PPIB, and ACTB
were amplified as references and normalization was performed using the NORMAgene data-driven normalization
algorithm.58
White blood cell differential:
Complete blood count was obtained from EDTA-treated blood via combined optical flow cytometry and
cellular impedance using an automated clinical hematology analyzer (Cell-Dyn, Abbott Diagnostics, Santa Clara,
CA).
Isolation of primary leukocytes for cell culture:
Starting with 30 mLs of healthy donor-derived EDTA-treated blood, peripheral blood mononuclear cells
(PBMCs) were separated from polymorphonuclear cells (PMNs) and RBCs via centrifugation over a
polysaccharide-sodium diatrizoate density gradient (Lymphoprep, 1.077 g/mL, StemCell Technologies) for 30
minutes at 400*g. Resultant interphase PBMC fractions were collected, resuspended in RPMI 1640 (Life
Technologies, Grand Island, NY) containing 10% autologous serum, separated into two aliquots, and set aside
at room temperature. Pelleted PMN/RBCs were immediately placed on ice for PMN enrichment via RBC lysis
induced by two 5 minute incubations with a 1:10 volume of ice cold ammonium chloride (ACK) buffer. The
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resultant PMNs were rinsed in ice cold PBS, counted via automated cytometer (Cellmeter X1, Nexcelom
Bioscience, Lawrence, MA), and immediately plated for experiments.
Following PNM isolation, monocytes were further enriched from one aliquot of PBMCs via a second round
of density gradient centrifugation as described by Menck et al.59 Briefly, PBMC suspensions were layered over
an iso-osmotic 46% Percoll (1.131 g/mL, Sigma Aldrich) solution prepared in RPMI 1640 containing 10%
autologous serum and centrifuged at 500*g for 30 minutes. Monocytes were collected from the resultant
interphase, rinsed in PBS, counted, and immediately plated for experiments.
Following PMN and monocyte isolation, the remaining aliquot of PBMCs was rinsed in PBS and seeded
in T75 flasks for lymphocyte expansion. Lymphocytes were expanded for 72 hours under standard mammalian
cell culture conditions in a growth media comprised of RPMI 1640 containing 2% PHA-M (Gibco, Grand Island,
NY), 2 mM L-Alanyl-Glutamine (GlutaMAX, Gibco), 25 mM HEPES (Gibco), 50 uM BME (Gibco), and 1%
antibiotic antimycotic (Gibco), supplemented with 10% autologous serum. Following expansion, actively
proliferating lymphocytes were rinsed in PBS, counted, and plated for experiments.
Neutrophil culture:
Neutrophils from healthy donors were seeded in 12-well plates at a density of 7.5*105 cells per well in
250 uL of RPMI 1640 containing 10% patient serum along with either Marimastat (10 uM, Sigma Aldrich, StLouis, MO), TAPI-0 (10 uM, Sigma Aldrich), or vehicle (DMSO, Fisher Scientific). Following three hours of
incubation under standard mammalian culture conditions, cells were lysed in NP40 lysis buffer (Life
Technologies) and cellular ADAM17 activity was assessed via enzyme activity assay. Cell culture supernatants
were collected and concentrations of sCD163 were quantified via ELISA; levels of neutrophil-derived sCD163
were determined by subtracting the concentration of sCD163 in media incubated without cells from the
concentrations of sCD163 observed in cell culture supernatants.
Monocyte culture:
Monocytes from healthy donors were seeded in 12-well plates at a density of 1*106 cells per well in 250
uL of RPMI 1640 containing 20% patient serum along with either Marimastat (10 uM), TAPI-0 (10 uM), or vehicle
(DMSO). Following three hours of incubation under standard mammalian culture conditions, cells were lysed in
NP40 lysis buffer and cellular ADAM17 activity was assessed via enzyme activity assay. Cell culture
supernatants were collected and concentrations of sCD163 were quantified via ELISA; levels of monocytesderived sCD163 were determined by subtracting the concentration of sCD163 in media incubated without cells
from the concentrations of sCD163 observed in cell culture supernatants.
sCD163 depletion from human serum:
sCD163 was depleted from pooled serum samples via immunoprecipitation using biotinylated goat
polyclonal antibody raised against the extracellular region of CD163 (BAF1607, R&D Systems, Minneapolis,
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MN). Biotinylated normal goat IgG (BAF108, R&D Systems) was used as an immunoprecipitation control.
Immunoglobulins were conjugated to polymer-coated superparamagnetic beads (Dynabeads Streptavidin T1,
Thermo Fisher, Waltham MA) at a ratio of 40 ug of immunogloulins per 1 mg of beads. For immunoprecipitation,
5 mL of pooled serum was precleared with 2.5 mg of unconjugated beads, and then incubated with 2.5 mg of
conjugated beads for 12 hours at 4ºC. Beads were subsequently separated from serum samples via multiple
rounds of magnetic separation. Following immunoprecipitation, pooled serum was filtered at 14 microns to
remove potential microbial contaminants prior to cell culture. Depletion of sCD163 was subsequently confirmed
via ELISA (Supplemental Figure 4).
Lymphocyte proliferation assay:
Expanded lymphocytes from healthy donors were seeded in 48 well plates at 5*104 cell per well in 200
uL growth media supplemented 20% pooled patient serum. Following 48 hours of culture, BrdU (Roche Life
Sciences, Indianapolis, IN) was added to cultures at a final concentration of 20 uM. After allowing for 24 hours
for BrdU incorporation, lymphocytes were adhered via centrifugation and fixed for BrdU quantification.
Incorporated BrdU was quantified via colorimetric ELISA (Roche Life Sciences) per manufacture instructions.
sCD163 ELISA:
sCD163 was measured in plasma samples and cell culture supernatants using a commercially available
ELISA assay (RAB0082, Sigma-Aldrich). Plasma samples were diluted 1:50, neutrophil cell culture supernatants
were diluted 1:5, and monocyte cultures were diluted 1:10 prior to analysis. Due to the potential confound of
hemolysis on concentrations of leukocyte derived analyites, plasma samples were screened for hemolysis prior
to ELISA. Plasma absorbance was measured at 385 and 414 nm via spectrophotometry (NanoDrop, Thermo
Scientific, Waltham, MA) and used to calculate a hemolysis score as described by Appierto et al.60 Hemoglobindepleted plasma (HemogloBind, Biotech Support Group, Monmouth Junction, NJ) spiked with serial dilutions of
sonicated red blood cells were used as a positive control. Plasma samples with detectable hemolysis were
excluded from analysis.
ADAM17 activity assay:
Total hemocyte fractions were thawed, mixed with NP-40 lysis buffer (Thermo Fisher) at a 1 to 1 ratio,
and depleted of hemoglobin via the HemogloBind hemoglobin removal kit (Biotech Support Group, Monmouth
Junction, NJ) as described by Park et al.61 Protein concentrations of hemoglobin-depleted total hemocyte lysates
and cell culture lysates were determined via DC-protein assay (Bio-Rad, Hercules, CA). ADAM17 activity was
measured in 25 ug of total hemocyte lysate, or 10 ug of cell culture lysate, via the InnoZyme TACE activity kit
(EMD Millipore, Temecula, CA) per manufacture instructions. Due to the reversible nature of ADAM17 inhibition
by both marimastat and TAPI-0, experimental concentrations of drug were maintained in assay buffers when
testing samples from inhibitor-treated conditions.
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Phase Contrast Microscopy:
Phase contrast images of primary leukocyte cultures were obtained from an AxioObserver inverted
microscope (Ziess, Thornwood, NY) equipped with a AxioCam mR5 digital camera (Ziess) using the AxioVision
imaging software suite (Ziess). Scale bars were generated via imaging of a 0.07-1.50 mm scale calibration slide
(Motic, Richmond, BC, CA).
Statistical analysis:
Parametric statistical analysis was performed using SPSS (IBM, Chicago, Ill) in combination with R 2.14
via the SPSS R integration plug-in. Chi-squared tests were used for comparison of dichotomous variables.
Student t-tests or one-way ANOVA were used for comparison of continuous variables. Spearman’s rho was used
to assess the strength of correlational relationships. The level of significance was established at 0.05 for all
parametric statistical testing. In the cases of multiple comparisons, p-values were adjusted using the Bonferonni
method.
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Figure Legends:
Table 1. Clinical and demographic characteristics.
Table 2. Clinical and demographic characteristics of subject sub-populations used for in vitro experiments.
Figure 1. ADAM17 and CD163 expression in the peripheral blood following ischemic stroke.
mRNA expression of (A) ADAM17 and (B) CD163 in peripheral whole blood obtained from AIS patients and
controls, with expression levels presented as fold difference relative to asymptomatic control group. (C) Cellular
ADAM17 activity in the peripheral whole blood of AIS patients and controls. (D) Plasma concentrations of
sCD163 in AIS patients and controls. (E) Relationship between peripheral blood cellular ADAM17 activity and
NIHSS within the AIS group. (F) Relationship between plasma sCD163 levels and NIHSS within the AIS group.
Intergroup comparisons were made via one-way ANOVA with subsequent Bonferonni post-hoc, while strength
of correlational relationships were tested via Spearman’s rho.
Figure 2. Relationship between plasma sCD163 levels and post-stroke peripheral immune status.
Relationships between plasma sCD163 levels and (A) absolute lymphocyte counts, (B) absolute monocyte
counts, and (C) absolute neutrophil counts in the peripheral blood of AIS patients. strength of correlational
relationships were tested via Spearman’s rho.
Figure 3. Effects of ischemic stroke serum on neutrophil ADAM17-dependant sCD163 production.
(A) Morphology of healthy donor-derived neutrophils following three hours incubation with 10% serum obtained
from AIS patients and control subjects, in either the presence and absence of ADAM17 inhibitors. (B) ADAM17
activity in neutrophil lysates collected following treatment. (C) Neutrophil-derived sCD163 levels in cell culture
supernatants collected following treatment, presented as the difference in sCD163 levels observed between cell
culture supernatants and serum-supplemented media incubated in the absence of cells. Intergroup comparisons
were made via one-way ANOVA with subsequent Bonferonni post-hoc.
Figure 4. Effects of ischemic stroke serum on monocyte ADAM17-dependant sCD163 production.
(A) Morphology of healthy donor-derived monocytes following three hours incubation with 20% serum obtained
from AIS patients and control subjects, in either the presence and absence of ADAM17 inhibitors. White
arrowheads indicate cytoplasmic vacuoles. (B) ADAM17 activity in monocyte lysates collected following
treatment. (C) monocyte-derived sCD163 levels in cell culture supernatants collected following treatment,
presented as the difference in sCD163 levels observed between cell culture supernatants and serumsupplemented media incubated in the absence of cells. Intergroup comparisons were made via one-way ANOVA
with subsequent Bonferonni post-hoc.
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Figure 5. Influence of post-stroke peripheral blood sCD163 levels on the capacity to support lymphocyte
proliferation.
(A) Morphology of healthy donor-derived lymphocytes following 72 hours of PHA-stimulated proliferation in the
presence of 20% serum obtained from AIS patients and controls, which was either unmanipulated in terms of
sCD163 levels, or depleted of sCD163 via immunoprecipitation using anti-CD163 monoclonal antibody. White
arrowheads indicate clusters of blasting lymphocytes. (B) BrdU incorporation over the final 24 hours of treatment.
Intergroup comparisons were made via one-way ANOVA with subsequent Bonferonni post-hoc.
Supplemental Table 1. Demographic characteristics of healthy leukocyte donors.
Supplemental Table 2. Clinical and demographic characteristics of subject subpopulations used for
independent replicate in vitro experiments.
Supplemental Figure 1. Relationships between post-stroke peripheral blood cellular ADAM17 activity and
plasma sCD163 levels and infarct volume.
(A) Relationship between peripheral blood cellular ADAM17 activity and infarct volume within the validation
cohort AIS group. (B) Relationship between plasma sCD163 levels and infarct volume within the validation cohort
AIS group. Strength of correlational relationships were tested via Spearman’s rho.
Supplemental Figure 2. Effects of ischemic stroke serum on neutrophil ADAM17-dependant sCD163 production
in an independent replicate experiment.
(A) ADAM17 activity in healthy-donor neutrophil lysates collected following three hours incubation with 10%
serum obtained from AIS patients and control subjects, in either the presence and absence of ADAM17 inhibitors.
(B) Neutrophil-derived sCD163 levels in cell culture supernatants collected following treatment, presented as the
difference in sCD163 levels observed between cell culture supernatants and serum-supplemented media
incubated in the absence of cells. Intergroup comparisons were made via one-way ANOVA with subsequent
Bonferonni post-hoc.
Supplemental Figure 3. Effects of ischemic stroke serum on monocyte ADAM17-dependant sCD163 production
in an independent replicate experiment.
(A) ADAM17 activity in healthy-donor monocyte lysates collected following three hours incubation with 10%
serum obtained from AIS patients and control subjects, in either the presence and absence of ADAM17 inhibitors.
(B) Monocyte-derived sCD163 levels in cell culture supernatants collected following treatment, presented as the
difference in sCD163 levels observed between cell culture supernatants and serum-supplemented media
incubated in the absence of cells. Intergroup comparisons were made via one-way ANOVA with subsequent
Bonferonni post-hoc.
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Supplemental Figure 4. Confirmation of serum sCD163 depletion using immunoprecipitation.
(A) Concentrations of sCD163 in pooled serum samples obtained from validation cohort AIS patients and controls
measured with ELISA following immunoprecipitation via either anti-CD163 polyclonal antibody or isotype control
immunoglobulin.
Supplemental Figure 5. Influence of post-stroke peripheral blood sCD163 levels on the capacity to support
lymphocyte proliferation in an independent replicate experiment.
(A) BrdU incorporation in healthy donor-derived lymphocytes over the final 24 of 72 hours PHA-stimulated
proliferation in the presence of 20% serum obtained from AIS patients and controls, which was either
unmanipulated in terms of sCD163 levels, or depleted of sCD163 via immunoprecipitation using anti-CD163
monoclonal antibody.
Supplemental Figure 6. Proposed role for CD163 in modulation of the stroke-induced peripheral immune
response.
Stroke-driven elevations in circulating levels of damage associated molecules (DAMs), proinflammatory
cytokines, and hormones coordinately trigger innate immune system activation and ADAM17-dependant CD163
shedding by monocytes, resulting in increased generation of sCD163. Heightened circulating sCD163 levels
subsequently act to suppress lymphocyte activity, likely as a means of limiting the risk of a CNS-directed
autoimmune response resulting from adaptive immune system activation.
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